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Chapter 1 
generAl introduCtion

1INTRODUCTION
generAl introduCtion 
The transmembrane protein pumps, ATP-binding cassette (ABC) transporters, protect living cells 
from naturally occurred toxins as well as exert multiple functions in biological pathways. However, 
they may be adopted by tumor cells to eliminate therapeutics and convey therapy resistance. It is 
noted that these transporters are also involved in preserving tissue stem cell integrity by efflux of 
differentiation inducing agents. The role of transporters during the development of cancer stem 
cells, abnormal precursors that give rise to malignant progeny, has been previously investigated. 
Their implication has been intensively studied in hematopoiesis, the most delineated differentiation 
hierarchy. Here, we have explored the function of ABC proteins at different stages of development 
– prenatal, postnatal and adult and at disparate conditions: normal and malignant hematopoiesis. 
The thesis starts with an overview of normal hematopoiesis and leukemia development. 
Where do the first Blood Cells Come from? emBryoniC  
Vs Adult hemAtopoiesis
embryonic system
Two hematopoietic systems exist, one primitive and one definitive, both arising during embryonic 
development but only one persisting though the life span. The embryonic hematopoietic system 
discussed here is based on mice studies. In mice, the first transient wave of hematopoiesis, termed 
primitive hematopoiesis, takes place at Embryonic Day (E) 7.0 in the yolk sac (YS) [1], represented by 
the generation of a unique population of primitive erythroid progenitors. These progenitors mature 
into large primitive erythroblasts expressing both embryonic and adult hemoglobins. There is not 
a clear-cut definition for the second phase of hematopoiesis, definitive hematopoiesis, since two 
independent anatomical sites are involved. At E.8.25 highly proliferative mixed lineage and myeloerythroid 
hematopoietic progenitor cells (HPCs) arise from the YS [1,2], which are capable of repopulating neonatal 
but not adult mice. The erythroid component of these HPCs derives smaller cells expressing only adult 
hemoglobin. The onset of embryonic cardiac contraction (at E8.25) drives these definitive HPCs to 
the embryo proper and to seed para-aotic splanchnopleura at E8.5 [3,4]. However, the pluripotent 
hematopoietic stem cells (HSCs) that provide the foundation of the differentiation hierarchy emerge at 
E10.5 at an intraembryonic region surrounding the dorsal aorta [1,5,6], the aorta-gonads-mesonephros 
(AGM) region. Both yolk sac HPCs and AGM HSCs subsequently seed through circulation of the fetal 
liver, thymus, spleen and ultimately at birth the bone marrow [1,7]. Recently, additional hematopoietic 
activity has been found in the placenta during the AGM and fetal liver period (Figure 1) [5,8-10]. It remains 
unclear whether placenta HSCs arise through de novo generation or colonization upon circulation.
It is natural, then, to question what the direct precursors are for the first HSCs. It is the 
endothelial cells from E.10 embryonic aorta, but not the E.8.25 HPCs from the YS, that give rise to 
the HSCs under the proper supportive microenvironment and with adequate blood flow [11-13]. 
Many surface markers overlap between endothelial and hematopoietic cells, such as SCL, FLK-1, 
CD34, vascular endothelial (VE)-cadherin (CD144) and VEGF-R2 [1,5]. Actually hematopoietic 
potential has been detected in umbilical arteries but not in umbilical veins [1,14], suggesting HSCs 
arise predominantly during artery specification in the definitive hematopoiesis. Hematopoietic 
clusters, which are demonstrated to be derived from aortic endothelial cells, are present on the 
floor of the dorsal aorta in various species [1,5,15]. This strongly supports the notion of (arterial) 
hemogenic endothelium as the direct precursor for AGM HSCs. 
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Figure 1. Developmental Regulation of Hematopoiesis in the Mouse. (Figure from Orkin et al. 
2008, republication permitted by Elsevier Copyright Clearance Center.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure  1.  developmental regulation of hematopoiesis in the mouse. (A) Hematopoiesis 
occurs first in the yolk sac (YS) blood islands and later at the aorta-gonad mesonephros 
(AGM) region, placenta, and fetal liver (FL). YS blood islands are visualized by LacZ staining of 
transgenic embryo expression GATA-1-driven LacZ. AGM and FL are stained by LacZ in Runx1-
LacZ knockin mice. (Photos courtesy of Y. Fujiwara and T. North.) (B) Hematopoiesis in each 
location favors the production of specific blood lineages. Abbreviations: ECs, endothelial 
cells; RBCs, red blood cells; LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-
term hematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid 
progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage 
progenitor. (C) Developmental time windows for shifting sites of hematopoiesis. (Figure from 
ref5, Orkin and Zon. 2008, republication permitted by Elsevier Copyright Clearance Center).
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The HSCs, generated de novo or migrated to a subsequent hematopoietic site, depend on the 
local microenvironment -- the niche -- for the regulation of survival, proliferation (self-renewal) 
and differentiation [1,5,16,17]. In adults, HSC and their progeny develop in close relation with 
mesenchymal-origin stromal cells, mainly constituted by fibroblasts, osteocytes, adipocytes and, 
most importantly, osteoblasts. Supportive mesenchymal stromal cells were discovered both in 
embryonic sites of hematopoiesis (YS and AGM) and in fetal liver [18,19]. Interestingly, the AGM 
microenvironment is the best supportive environment for HSCs in the E11 embryo [1,19]. In fact it 
has been demonstrated that direct contact between hematopoietic cells from embryonic tissues 
and embryonic stromal cell lines is required to maintain HSC activity in culture [20]. The properties 
of HSCs in each site differ, presumably reflecting the diverse niches where they are supported as 
well as their stage of differentiation [5]. For instance, adult bone marrow HSCs are largely quiescent, 
whereas the HSCs in the fetal liver are in cycle. 
Adult system
The life-long maintenance of blood cell production depends on the divisions of HSCs that are mainly 
asymmetric and yield both differentiating progenies as well as new HSCs via self-renewal. Here the 
topic moves to human hematopoiesis. The HSCs reside as rare cells in the bone marrow and sustain 
self-renewal capability through successive divisions securely enough to maintain clones that persist 
life-long (Figure 2) [5]. The classical hematopoiesis hierarchy has been believed for decades. The 
most primitive long-term repopulating stem cells (LT-HSCs, Lin− Sca-1+ Kit+ Flt3− CD34− CD49b-), 
are detected by their capacity to generate circulating monocytes, granulocytes and lymphocytes 
16-44 weeks post-transplant, representing extended self-renewal. While bone marrow HSCs also 
contains other populations with limited self-renewal, which yield lymphomyeloid grafts only within 
6-8 months or 2-4 weeks, termed intermediate-term HSCs (IT-HSCs, CD34- Flt3- CD49b+) and short-
term repopulating cells (ST-HSCs, CD34+, lineage−, c-Kit+, Sca-1+), respectively [21,22]. This suggests 
stem cell differentiation initiates from the loss of mechanisms that stabilize self-renewing behavior 
throughout successive divisions [22]. ST-HSCs give rise either to the common myeloid progenitors 
(CMPs) or to the common lymphoid progenitor cells (CLPs). The CLPs differentiate into the mature 
lymphocytes (the T- and B- cells) and Natural Killer (NK) cells. The CMPs further develop into the 
megakaryocytic/erythrocytic progenitors (MEPs) or the granulocyte/macrophage progenitors 
(GMPs), each giving rise to a distinct set of functional blood cells. The production of erythrocytes 
is tightly regulated and adjusted rapidly in response to non-physiological stresses. Beginning 
with a small pool of pluripotent stem cells, erythropoiesis requires successive combinations of 
transcription factors, which dictate the expression of adhesion and growth factor receptors along 
the serial maturation stages of erythroid progenitors (BFU-E, CFU-E, pro-, intermediate- and late- 
erythroblasts) [5,23] (Figure 2A). 
The classical model of hematopoiesis assumes that hematopoietic stem cells are ‘naïve’ in 
that they express no lineage specific genes until the commitment sets in. However, in reality both 
single HSCs and multipotential progenitors express markers of disparate lineages, albeit generally 
at low levels, suggesting the fate of immature cells is not sealed [24,25]. This phenomenon is 
termed lineage priming [26]. Recent studies based on lineage priming [27] have proposed another 
model of cellular hierarchy of human stem/progenitor cells and cascade of lineage-affiliated 
gene signatures. In this refined model MPPs (CD34+CD38-CD90-CD45RA-), derived from HSCs 
(CD34+CD38-CD90+CD45RA-), give rise to MEP primed progenitors and CD38-CD45RA+ lymphoid-
15
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Figure 2. Models of hematopoiesis. (Figures from Goardon et al. 2011, republication permitted by 
Elsevier Copyright Clearance Center) 
 
figure  2. models of hematopoiesis. (A) Classical model with requirements of Transcription 
Factors in Hematopoiesis. The stages at which hematopoietic development is blocked in the 
absence of a given transcription factor, as determined through conventional gene knockouts, are 
indicated by red bars.  Those factors in light font have not yet been found translocated or mutated 
in human/mouse hematologic malignancies. Abbreviations: LT-HSC, long-term hematopoietic 
stem cell; ST-HSC, short-term hematopoietic stem cell; CMP, common myeloid progenitor; CLP, 
common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/ 
macrophage progenitor; RBCs, red blood cells. (B) Refined model of lineage priming. MPPs, 
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primed multipotential progenitors (LMPPs). LMPPs can differentiate into CD38+ GMPs or lymphoid 
cells (Figure 2B), although not capable of engraftment in xenotransplantation assays [27]. However, 
a careful dissection of mechanisms that allow the erythroid - megakaryocyte lineage to separate 
from the LMPP lineage still needs to be developed. Interestingly, we have found that the balance 
between MEPs and GMPs is tuned by the expression level of a mitochondrial transporter ABCB10 
(see chapter 5 and 6). 
 The capacity of HSCs to reconstitute the entire blood system of a recipient is exploited in 
the treatment of hematopoietic failure or malignancies. For clinical and research purposes, the 
major resources of human HSCs and committed progenitors are the bone marrow (BM) and 
umbilical cord blood (CB) [28,29]. BM- or CB- derived hematopoietic stem/progenitor cells can be 
identified and isolated by their expression of the CD34 membrane phosphoglycoprotein. CD34+ 
cells account for 1-2% of normal adult mononuclear cells and contain myeloid, erythroid and 
lymphoid precursors as well as pluripotent stem cells. In human, HSCs can be further enriched in 
CD34+CD38- population [30], comprising only 1-10% of the CD34+ cells, as shown by long-term 
in vitro cultures and transplantation experiments. CD38 is a type II transmembrane glycoprotein, 
considered one of the nucleotide-metabolizing ecto-enzyme family, which functions mainly 
through scavenging extracellular nucleotides and tuning purinergic signaling. It may be involved 
in the differentiation of the B lymphocyte compartment. CD34+CD38- cells can be further divided, 
as described earlier, into the lin-CD34+CD38-CD90+CD45RA- compartment, where HSCs reside, 
and the lin-CD34+CD38-CD90-CD45RA- multipotential progenitors (MPPs) with lymphomyeloid 
potential [27].
hemAtopoiesis: mAintenAnCe of A tightly regulAted 
hierArChy And the pAthologiC effeCts of its disruption – 
deVelopment of leukemiA 
regulation of hematopoiesis
The process of proliferation and differentiation of HSCs is strictly controlled by genetic programs, 
the niches and growth factors. Transcription factors required to program hematopoietic fate 
function in a temporal- and stage-specific manner [5], reflecting parsimony with regard to the 
repertoire of factors needed to achieve complex gene regulation. Definitive HSCs derived from 
different sites (fetal liver or bone marrow) or in individuals at different ages compose disparate 
transcription factors. Factors essential for emerging HSCs include SCL/tal-1 together with its 
protein partner LMO2 (no blood cells are generated in their absence) [31], Runx1 (required for 
hematopoietic clusters), GATA2 [32], MLL [33] [34] and a few others [32]. The overview of known 
(Figure 2 legends continued) derived from HSCs, give rise to MEP primed progenitors and 
CD38-CD45RA+ lymphoid-primed multipotential progenitors (LMPPs), which can differentiate 
into GMPs or lymphoid cells. However, the cancer stem cells are not corresponding solely 
to the normal stem cells. Sometimes leukemic stem cells (LSCs) may reside in more mature 
CD34+CD38+ GMPs (GMP-like LSCs) and even CD34- compartments. (Figure A from ref 5, Orkin 
and Zon. 2008; Figure B from ref 27, Goardon et al. 2011, republication permitted by Elsevier 
Copyright Clearance Center).
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factors, whose absence blocks hematopoietic development at certain stages, is depicted in 
Figure 2A. However, inactivation of SCL/tal1 and Runx1 in adult HSCs only perturbs differentiation 
of specific lineages but has little consequence on maintenance or self-renewal of HSCs [35]. 
Interestingly, the correspondence of lineage-restricted transcription factors and progenitors does 
not comply with a one-to-one rule (lineage priming) [26]. The action of key lineage-restricted 
factors is context dependent and is antagonistic to other regulators: they are endowed with the 
complementary capabilities of promoting their own lineage differentiation while simultaneously 
acting against regulators favoring other choices.
development of acute myeloid leukemia
A highly efficient and flawless hematopoiesis is demanded by the constant requirement of new 
mature blood cells. Typically, leukemia is defined as deregulation of this process that leads to 
accumulation of immature cells with arrested differentiation, growth factor independent 
proliferation and a decreased susceptibility to apoptotic stimuli, resulting in clinical manifestation. 
Propagation of defective immature cells in the bone marrow will eventually drive them into the 
peripheral blood due to space restriction. The presence of more than 20% immature progenitor 
cells (leukemic blasts) in the bone marrow is called acute leukemia. Acute myeloid leukemia arises 
from the sequential accumulation of mutations at the level of the hematopoietic stem/progenitor 
cell, resulting in disturbed balance of proliferation, differentiation and apoptosis of immature 
progenitors [36].
Hematopoietic cell fate is intertwined with the origination of leukemias, as the majority 
of transcription factors guiding hematopoiesis are involved in somatic mutations in human 
hematopoietic malignancies [5,37-40]. Seminal studies in AML have led to the cancer stem cell 
(CSC) hypothesis [41], which postulates that cancers are hierarchically organized, mirroring normal 
tissues. The CSCs, sitting at the apex of the cancer hierarchy, are multipotent and with marked self-
renewal capacity [41]. It was believed that inherited or acquired genetic abnormalities at the level 
of HSCs lead to defective downstream process of hematopoiesis [5,42-45]. However, mutations 
typical for leukemia, such as t(8:21), at the HSC level do not necessarily mean that these mutation-
bearing cells are leukemic themselves [27]. This rather represents a pre-leukemic abnormality. 
The genuine initiator of leukemia may also be the progeny of pre-leukemic HSCs, the progenitor 
endowed with a “stem cell-like” signature by additional deregulations [46]. The progenitor derived 
leukemic strem cells (LSCs) possess hybrid characteristics, retaining the proliferative potential of 
progenitors, not seen in quiescent stem cells, and specifically acquiring pathological self-renewal 
capacity [27]. In most cases, LSCs reside in both CD34+CD38- LMPPs (LMPP-like LSCs) and more 
mature CD34+CD38+ GMPs (GMP-like LSCs) [27] and sometimes even in differentiated CD34- 
compartments [47] (Figure 2 B). The LSCs of progenitor origin exceed their normal counterparts 
remarkably by extensive engraftment potential [27].
Leukemia is not the consequence of non-specific genetic or epigenetic effects but rather the 
end result of attacks at vulnerable points in a network. A growing list of genes have been found to 
be mutated in leukemia, categorized into signal transduction components [48], transcription factors 
[5], epigenetic regulators [49,50], oxidative stress mediators [51] and ubiquitination elements [52] 
etc. Alterations in tumor suppressors, oncogenes and transcription factors in turn activate certain 
ABC drug transporter genes [53,54]. This leads to constitutive overexpression of ABC genes in some 
drug-naïve leukemic stem cells that are intrinsically resistant to chemotherapy [55,56].
18
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Atp-Binding CAssette (ABC) trAnsporters:  
struCture And funCtions
structure based multiple specific substrate binding
The ATP-binding cassette (ABC) transporter genes represent the largest transmembrane protein 
family, widely dispersed in the genome and encompassing 49 members in human, divided into 
7 subfamilies (A to G) [53,57]. Highly conserved throughout evolution, they are present in all 
living organisms, spanning a range from prokaryotes to mammal. By using the energy released 
from ATP-binding and hydrolysis, these proteins transport a wide variety of structurally unrelated 
substances across extra- and intracellular membranes, including hormones, lipids, peptides, 
metabolic products, drugs and naturally occurring toxins. They are required for many physiological 
processes as well as stress management and tissue defense and are often associated with therapeutic 
evasion of tumors. 
A functional full transporter protein typically contains two ATP-binding domains, also known as 
nucleotide-binding folds (NBFs), and two transmembrane (TM) domains (Figure 3). The eukaryotic 
ABC genes are organized either as full transporters with motifs arranged as N-TM-NBF-TM-NBF-C, 
or as half transporters that must form homodimers or heterodimers to function. NBFs, located in 
the cytoplasm, are highly conserved and their sequence and organization form the basis of the 
classification of ABC genes. The NBFs contain characteristic motifs, Walker A and B, separated by 
approximately 90-120 amino acids. Just upstream of the Walker B site, an additional element is 
found in ABC genes, the signature C motif, distinguishing ABC subfamilies. The transmembrane 
 
Figure 3. Structural organization of ABC transporters. (Figure from Moitra et al. 2011, 
republication permitted by Nature Publishing Group Copyright Clearance Center) 
 
 
 
Figure 4. Model of substrate transport by P-gp. (Figure from Aller et al. 2009, republication 
permitted by Elsevier Copyright Clearance Center) 
figure 3. structural organization of ABC transporters. (a) Structural organization of an ABC 
(full) transporter. A full transporter contains two TMDs and two NBFs. (b) ABC transporters are 
driven by ATP. ABC transporters efflux substrates with the power provided by ATP hydrolysis. 
ABC, ATP-binding cassette; NBF, nucleotide-binding fold; TMD, transmembrane domain. 
(Figure from ref55, Moitra et al. 2011, republication permitted by Nature Publishing Group 
Copyright Clearance Center).
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domains contain 6-11 membrane-spanning α-helices and provide the specificity for the substrate. 
In the TMDs, a significant cavity constitutes a substrate binding chamber, facing to the exterior or 
to the cytoplasm in importers and exporters, respectively, which will be inverted when the NBFs 
transfer the energy necessary to translocate the allocrite (substrate) across the membrane [53,58]. 
As the best depicted paradigm in transporters, ABCB1 (MDR1/P-gp) has unusually broad poly-
specificity, recognizing hundreds of compounds from as small as 330 daltons up to 4000 daltons, most 
of which are hydrophobic and partition into the lipid bilayer. Pulling and expelling substances from 
the membrane, ABCB1 is likened to a molecular “hydrophobic vacuum cleaner”. The elegant article 
of Aller SG et al. [58] reveals the structure of ABCB1 as a molecular basis for poly-specific substance 
binding. The crystal structure of P-gp represents an inward-facing conformation with a drug-binding 
pocket (Figure 4). Many residues that interact with different drugs face the drug-binding pocket 
and are highly conserved, suggesting a common mechanism of poly-specific drug recognition. In 
the ground state, i.e. with the TMDs not bound to any allocrites, the NBF monomers are separated 
although positioned in close apposition, forming an open NBF dimer that can be always loaded with 
cellular ATP. When a substrate partitions into the internal drug-binding pocket through an open 
portal of the transembrane domain, the NBFs form the productive ATP sandwich dimmer and trigger 
the hydrolysis of ATP into ADP. This causes a large conformational change, presenting the substrate 
and drug-binding site to the outer leaflet or the extracellular space. The transport occurs mostly 
unidirectional, that is, from cytoplasm to the outside of the cell or into an intracellular compartment.
function of subfamilies
The ABCA subfamily (table 1) is composed of 12 full transporters, further divided into two subgroups. 
The first one contains 7 genes (ABCA1-4, ABCA7, ABCA12 and ABCA13) dispersed on 6 different 
chromosomes. The second group of 5 genes (ABCA5-6, ABCA8-10) is arranged in a cluster on 
Chromosome 17q24. ABCA family members share a cholesterol efflux related C-terminal motif and 
several of them are known to be involved in lipid transport or intracellular trafficking of peroxisomes 
or lysosomes, such as ABCA1, ABCA3, ABCA4 and ABCA7 [59-63]. Mutation in ABCA1 causes Tangier 
disease [64]. Additionally, ABCA2 is a strong genetic risk factor for early-onset Alzheimer’s disease 
[65,66]; ABCA13 has been associated with neurological disorders as well [59].
ABCB family contains both full (four) and half transporters (seven). ABCB1, p-glycoprotein (P-gp), 
is the first human ABC transporter cloned and characterized for its capacity to confer a multidrug 
resistance phenotype in cancer cells, primarily expressed in the liver and blood-brain barrier [58,67]. 
Half transporters ABCB2 (TAP1) and ABCB3 (TAP2) belong to the transporter associated with antigen 
processing (TAP) family, which is crucial for the adaptive immune system by aiding the presentation 
of proteasomal degradation products to MHC-I molecules [68]. The mitochondrial half transporters 
ABCB6-7 and ABCB10 are implicated in the sensing of oxidative stress and heme metabolism [69-72].
The ABCC family contains 13 full transporters with a diverse functional spectrum ranging from 
ion transport and toxin secretion to signal transduction. ABCC1, multidrug resistance protein 1(MRP1) 
is demonstrated to convey drug resistance and to transport a remarkable range of drugs, including 
organic anions, drugs conjugated to glutathione, glucuronate or sulphate and anthracyclines. ABCC 
2-5 and ABCC10-11 have been added to MRP members as well [55]. Mutations in ABCC members are 
responsible for pseudoxanthoma (ABCC6) [73] and cystic fibrosis (ABCC7) [74]. ABCC9 constitutes 
the regulatory subunit of an ATP-sensitive potassium channel [75].
20
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The ABCD subfamily includes 4 half transporters located in the peroxisome, which are only 
functional after homo- or hetero-dimerization. ABCD1 is implicated in the transport of coenzyme 
A esters of very-long-chain fatty acids. Mutations in ABCD1 and polymorphisms in ABCD1-4 have 
been associated with X-linked adrenoleukodystrophy [76,77]. 
The ABCE and ABCF family contain two NBFs but no TM domain, distinct from the other 
subfamilies. They are involved in translational control [78]. So far no disorders have been associated 
with the ABCE or ABCF genes.
The ABCG family comprises 5 members: ABCG1-2, ABCG4-5, and ABCG8. ABCG1 is differentially 
highly expressed in the HSCs compared to other stem cells, such as embryonic stem cells and 
mesenchymal stem cells [79]. ABCG2, another principal drug resistance related transporter besides 
ABCB1 and ABCC1, is also known as one of the markers for side population of stem cells [80,81].
stem Cells With unique ABC gene signAture
ABC proteins became related with stem cells by the identification of the “side population” (SP), a 
stem cell enriched fraction observed in both hematopoietic and solid tissues, which can be isolated 
based on ABCG2/ABCB1 dependent dye efflux. Stem cells possess the dual properties of self-renewal 
and pluripotency, which demands protection of the stem cell population throughout the life of an 
organism. One principal mechanism of stem cell protection is provided by multifunctional efflux 
 
Figure 3. Structural organization of ABC transporters. (Figure from Moitra et al. 2011, 
republication permitted by Nature Publishing Group Copyright Clearance Center) 
 
 
 
Figure 4. Model of substrate transport by P-gp. (Figure from Aller et al. 2009, republication 
permitted by Elsevier Copyright Clearance Center) figure 4. model of substrate transport by p-gp. (A) Substrate (magenta) partitions into the 
bilayer from outside of the cell to the inner leaflet and enters the internal drug-binding pocket 
through an open portal. The residues in the drug-binding pocket (cyan spheres) interact with 
QZ59 compounds and verapamil in the inward-facing conformation. (B) ATP (yellow) binds to 
the NBDs causing a large conformational change presenting the substrate and drug-binding 
site(s) to the outer leaflet and/or extracellular space. In this model of P-gp, which is based on 
the outward-facing conformation of MsbA and Sav1866, exit of the substrate to the inner leaflet 
is sterically occluded, which provides unidirectional transport to the outside. (Figure from 
ref58, Aller et al. 2009, republication permitted by Elsevier Copyright Clearance Center).
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table 1. Human ABC genes, subfamilies, chromosomal locations, and functions. (From Ref55, Moitra et al. 2011, 
republication permitted by Nature Publishing Group Copyright Clearance Center).
symbol subfamily Alias location function
Anticancer drug 
transport
ABCA1 A ABC1 09q31.1 Cholesterol efflux onto high-density lipoprotein
ABCA2 A ABC2 09q34.3 Drug transport yes
ABCA3 A ABC3 16p13.3 Surfactant secretion? Drug resisance yes
ABCA4 A ABCR 01p21.3 N-retinylidene-phosphatidylethanolamine efflux  
ABCA5 A ABC13 17q24.3
ABCA6 A   17q24.3    
ABCA7 A ABCX 19p13.3
ABCA8 A   17q24.3    
ABCA9 A 17q24.3
ABCA10 A   17q24.3    
ABCA12 A 02q34
ABCA13 A   07p12.3    
ABCB1 B MDR1 07q21.12 Multidrug resistance yes
ABCB2 B TAP1 06p21 Peptide transport  
ABCB3 B TAP2 06p21 Peptide transport
ABCB4 B PGY3 07q21.12 Phosphotidyl choline and drug transport yes
ABCB5 B ABC19 07p21.1 Drug transport
ABCB6 B ABC14 02q35 Iron transport  
ABCB7 B ABC7 xq21-22 Fe/S cluster transport
ABCB8 B ABC22 07q36.1    
ABCB9 B ABC23 12q24.31
ABCB10 B   01q42.13    
ABCB11 B SPGP 02q24.3 bile salt transport, drug transport yes
ABCC1 C MRP1 16p13.12 Drug resistance yes
ABCC2 C MRP2 10q24.2 Organic anion efflux, drug transport yes
ABCC3 C MRP3 17q21.33 Drug resistance yes
ABCC4 C MRP4 13q32.1 Nucleoside transport, drug transport yes
ABCC5 C MRP5 03q27.1 Nucleoside transport, drug transport yes
ABCC6 C MRP6 16p13.12 yes
ABCC7 C CFTR 07q31.31 Chloride ion channel  
ABCC8 C SUR 11p15.1 Sulfonylurea receptor
ABCC9 C SUR2 12p15.1 K(ATP) channel regulation  
ABCC10 C MRP7 06p21.1 Drug transport yes
ABCC11 C MRP8 16q12.1 Drug transport yes
ABCC12 C MRP9 16q12.1
ABCD1 D ALD xq28 VLCFA transport regulation  
ABCD2 D ALDL1 12q11
ABCD3 D PXMP1 01p22.1    
ABCD4 D PMP69 14q24.3
ABCE1 E OABP 04q31.31 Oligoadenylate binding protein  
ABCF1 F ABC50 06p21.1
ABCF2 F ABC28 07q36.1    
ABCF3 F ABC25 03q27.1
22
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ABC transporters. To further study this issue we examined the expression of 45 transporter genes 
in both leukemic and normal HSCs and observed a large set of ABC transporters similarly expressed 
in both stem cell compartments. However, in more committed progenitors, the expression level is 
lower [82]. Accumulating evidence [83-86] supports the assumption that ABC transporters maintain 
stem cell integrity by protecting them against xenobiotics. We then extended the transporter 
profiling study to other stem cell types [79] to investigate whether other non-related stem cells 
possess a similar ABC gene signature to HSCs. Unexpectedly, HSCs exhibit a significantly higher 
expression compared to other stem cells that showed a very similar transporter signature. In 
addition, in contrast to in HSCs, transporters were not downregulated upon differentiation in 
both adult derived and umbilical cord derived unrestricted somatic stem cells (USSCs). Notably, 
virtually all mature blood cells exhibited higher expression levels of specific transporters compared 
to HSCs. Therefore, the down-modulation of ABC genes at early stages of stem cell differentiation 
is restricted to hematopoietic tissues and is transient.
However, for tumor stem cells, one cannot exclude the possibility that high expression of ABC 
genes is a secondary consequence of malignant transformation through transcription regulation 
rather than a stem cell phenotype. Recently, a stem cell factor, SALL4, was identified to be one of 
the key genes involved in self-renewal capacity, and a key regulator for human leukemic cell survival 
[87,88]. Furthermore, its overexpression activates side population related transporters ABCA3 and 
ABCG2 via direct or indirect mechanisms [88]. This opens the discussion about the correlation 
between acquisition of self-renewal in cancer stem cells and ABC transporter expression.
mitoChondriAl ABC trAnsporters, oxidAtiVe stress And 
erythropoietiC disorders
Terminal erythroid differentiation requires remodeled mitochondrial iron uptake and processing 
directed toward maximizing hemoglobin synthesis at the time while cells become mature red blood 
cells for sufficient oxygen delivery [89] (the mature red cells already lose mitochondria to minimize 
their own oxygen consumption and leave space for hemoglobin). Developing erythrocytes adopt 
multiple machineries to maintain oxidative homeostasis since enzymes required for heme synthesis 
are vulnerable to oxidative damage [90,91]. 
Several mitochondrial transporters have been described to play a role in the biosynthesis 
and transport of heme and FeS clusters as well as for oxidative stress sensing. Localized to the 
mitochondria, ABCB6 imports porphyrins into mitochondria and up-regulates de novo porphyrin 
synthesis [92]. Its overexpression increases cytosolic heme and protects cells against oxidative stress 
table 1. Continued
symbol subfamily Alias location function
Anticancer drug 
transport
ABCG1 G White 21q22.3 Cholesterol transport?  
ABCG2 G BCRP 04q22 Toxin efflux, drug resistance yes
ABCG4 G White2 11q23    
ABCG5 G White3 02p21 Sterol transport
ABCG8 G White4 02p21 Sterol transport  
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whereas suppression of ABCB6 reversed these phenotypes [69]. In line with this, a recent study 
showed that ABCB6 is induced by arsenic trioxide via increased cellular reactive oxygen species 
and in turn protects cells against arsenic cytotoxicity [93]. 
ABCB7 is a FeS cluster exporter and mutations in this gene cause X-linked sideroblastic anemia 
with ataxia (XLSA/A) due to a large increase in iron accumulation in the mitochondria that was 
poorly available to mitochondrial ferritin [72]. The unifying characteristic of sideroblastic anemias 
is a pathological erythroid precursor, ring sideroblast, which contains excessive deposits of 
non-heme iron in mitochondria with perinuclear distribution resulting in a ring appearance. Lack 
of functional ABCB7 causes defects in iron-sulfur cluster assembly and iron-sulfur protein release 
from mitochondria. The failure of export of Fe/S proteins from mitochondria enhances iron input 
via the interaction between RNA iron responsive element (IRE) and iron regulatory proteins (IRP) 
and exaggerates the mitochondrial iron overload [72,94].
ABCB10 is located in the inner mitochondrial membrane, with its ATP-binding cassette directed 
into the mitochondrial matrix [70,71]. Substrates for ABCB10 remain unknown. During murine red cell 
development, Abcb10 gene expression is strongly induced by GATA-1 and forced Abcb10 expression 
in differentiated MEL cells enhances hemoglobin formation [70,95]. In agreement, we observed that 
ABCB10 is the most highly expressed transporter in CD71+ erythroid precursors [79]. Interestingly, 
recent work has revealed ABC-me, the murine homolog of human ABCB10, as a new gene required 
for cardiac recovery after ischemia/reperfusion through protection against oxidative stress [96]. 
Based on this, we hypothesized that ABCB10 is required for efficient human erythroid development. 
multidrug resistAnCe And trAnsCriptionAl regulAtion of ABC 
drug trAnsporters: more Complex thAn initiAlly BelieVed 
multidrug resistance
One major obstacle in repeated chemotherapy in leukemia and many other cancers is the 
development of multidrug resistance (MDR) [81,84,97]. MDR is the phenomenon that cells develop 
resistance to a combination of or even a single drug and additionally show cross-resistance 
to many other structurally and mechanistically unrelated drugs. Mechanisms for the onset of 
MDR include reduced drug uptake, failure of apoptosis, alterations in cell cycle checkpoints, 
increased DNA repair, activation of detoxifying enzymes and increased efflux of drugs [98,99]. 
Some members of the ABC transporter family possess the capacity to export a wide variety of 
structurally unrelated chemotherapeutical compounds from cancer cells, therefore supposed to 
be the founding molecular basis of MDR for decades. The identification of P-gp (ABCB1) by virtue 
of its overexpression in MDR tumor cells sparked the hope that its inhibition could be the key to 
eradicate this insidious form of resistance. Indeed, ABCB1 is responsible for the transport of several 
anticancer agents such as anthracyclines (DNR, doxorubicin), anthracenes (mitoxantrone), vinca 
alkaloids (vinblastine, vincristine), etoposide, topotecan as well as anti-human immunodeficiency 
virus agents and fluorophores. An ongoing search for agents that inhibit P-gp function has resulted 
in the discovery of many inhibitors for ABCB1, ranging from calcium channel blockers (verapamil), 
antiarrhythmics (quinidine) and hydrophobic peptides (cyclosporine A) to Fucidin. ABCB1 double 
knockout mice were found to be extremely sensitive to xenobiotic toxins. Later, the recognition 
of MRP1 (ABCC1) led to the realization that the MDR phenotype was considerably more complex 
than initially believed. ABCC1 was identified in the drug resistant human lung cancer cell line H69AR 
24
1INTRODUCTION
that did not overexpress ABCB1. Knockout of ABCC1 gave rise to hypersentitivity to etoposide in 
mice. Another member of ABC genes, to which MDR is attributed, is the half transporter ABCG2, or 
Breast Cancer Resistance Protein (BCRP). It was first described in the drug resistant breast cancer 
cell line MCF-7 that lack ABCB1 and ABCC1. ABCG2 confers resistance to topotecan, mitoxantrone, 
doxorubicin and related compound. ABCG2-/- mice are normally viable but display abnormalities 
in disposal of carcinogens. Currently, more than 10 ABC proteins have been implicated in a MDR 
phenotype and more will be likely added to this list with time, since abrogation of one or a few 
transporters failed to overcome clinical resistance to multiple anticancer agents. ABC genes involved 
in extrusion of chemotherapeutical compounds are described in table 1. 
transcriptional regulation of ABC transporters
MDR is far more complex than cancer cell adaptation by simply upregulating certain drug 
transporters. ABC proteins are not only the machinery adopted by malignant cells but also 
constitutive components of normal cells. They are needed for the biodistribution of xenobiotics 
and nutrients executed by normal living cells and they respond to a much broader range of apoptotic 
stimuli [56,100]. In a well delineated picture of transcriptional regulation of ABC drug transporters, 
the drug-mediated transporter regulation is deployed as only a tip of the iceberg.
The promoters of human drug-related transporters lack an appropriately positioned TATA box 
and instead contain an initiator (Inr) element. Expression of ABC transporters is tighly regulated, 
particularly at the level of transcription. The constitutive (uninduced) transcription in normal 
tissues is mostly attributed to ‘GC’ boxes and CCAAT elements in Inr promoters that interact with 
different transcription factor families (such as NF-Y, Sp1 and Sp3) through sequence-specific DNA 
recognition. Oncogenes or tumor suppressors, such as p53, AP-1, WT-1 and APC, may interact with 
specific binding elements (e.g., the MED-1 site, multiple start site element downstream, and HT 
site, a p53 DNA binding element) as well as the GC-rich binding site in the promoters of transporter 
genes, functioning as suppressor in their wild type form but as activator in certain mutant forms [56]. 
Thus, high levels of expression of multidrug transporters are often observed in drug-naïve tumor 
cells due to their enhanced constitutive transcription in the process of malignant transformation. 
Notably, the drug resistant genes are highly responsive to a broad range of stimuli, including 
heat shock, inflammation, hypoxia, carcinogens as well as chemotherapeutics, bringing about 
their induced expression. Unique promoter elements that interact with specific type of stimuli 
are underlying transporter induction, involving transcription from different initiation sites. For 
example, 2-acetylaminofluorene (2-AAF) activates rat mdr1b through the generation of reactive 
oxygen species, leading to the activation of NF-κB that interacts with an NF-κB-binding site at 
position -167 to -158 within the promoter. In humans, this carcinogen activates phosphoinositide 
3-kinase and its downstream effectors Rac1, NAD(P)H oxidase and Akt, resulting in activation of 
MDR1 through an upstream element (-6092) including an NF-κB-binding site. Thus, transporter 
regulation after drug treatment might also be a secondary response to downstream cellular stress. 
Species unique promoter elements may cause different regulation of ABC transporters.
sCope of this thesis
The initiative of this thesis was to identify candidate transporter genes essential for hematopoiesis 
and drug responses. We investigated the role of transporters in hematopoietic stem cells by first 
analyzing their expression, comparing it to different stem cells as well as differentiated blood cell 
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fractions (Chapter 2). We found that HSCs possess a unique transporter signature compared to 
other stem cells, suggesting HSCs rely on a different repertoire of transporters. Strikingly, virtually 
all mature blood cells exhibited higher expression levels of specific transporters compared to 
HSCs. This might indicate that specific transporters are required for cell-type related functions in 
mature blood cells and that a unique transporter expression signature is important for stem cell 
physiology. We further investigated the alteration in transporter expression following chemotherapy 
(Chapter 3). Surprisingly, transporter expression was highly heterogeneous amongst patients 
even before therapy. Furthermore, the therapy-induced alterations in gene expression were also 
found to be tumor cell specific and thus may contribute to differences in responses to therapy. 
Subsequently, we screened two candidate mitochondrial transporters ABCB8 and ABCB10, which 
were potentially involved in myeloid leukemia transformation via oxidative stress regulation, for 
mutations / polymorphisms in AML patients (Chapter 4). As they turned out to contain no genetic 
abnormality in myeloid leukemia and ABCB10 is known to be strongly induced during erythroid 
differentiation, we eventually focused our efforts on investigating the role of ABCB10 in red blood 
cell development. Our results showed that ABCB10 was required for efficient erythropoiesis and 
that it influenced the equilibrium between red and white blood cell generation (Chapter 5). We 
leave to the future investigators the questions how ABCB10 is regulated at the transcriptional level 
in terms of specific promoter elements and the binding factors, and how erythroid and myeloid 
development is regulated by intracellular reactive oxygen species (Chapter 6).
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Chapter 2 
ABC TRANSPORTER EXPRESSION PROFILES IN STEM CELLS
ABstrACt
Background: ATP-binding cassette (ABC) transporters protect cells against unrelated (toxic) 
substances by pumping them across cell membranes. Earlier we showed that many ABC transporters 
are highly expressed in hematopoietic stem cells (HSCs) compared to more committed progenitor 
cells. The ABC transporter expression signature may guarantee lifelong protection of HSCs but may 
also preserve stem cell integrity by extrusion of agents that trigger their differentiation. Here we 
have studied whether non-hematopoietic stem cells (non-HSCs) exhibit a similar ABC transporter 
expression signature as HSCs. 
results: ABC transporter expression profiles were determined in non-hematopoietic stem cells 
(non-HSCs) from embryonic, neonatal and adult origin as well as in various mature blood cell types. 
Over 11,000 individual ABC transporter expression values were generated by Taqman Low Density 
Arrays (TLDA) to obtain a sensitivity comparable with quantitative real-time polymerase chain 
reactions. We found that the vast majority of transporters are significantly higher expressed in HSCs 
compared to non-HSCs. Furthermore, regardless their origin, non-HSCs exhibited strikingly similar 
ABC transporter expression profiles that were distinct from those in HSCs. Yet, sets of transporters 
characteristic for different stem cell types could be identified, suggesting restricted functions in 
stem cell physiology. Remarkably, in HSCs we could not pinpoint any single transporter expressed 
at an evidently elevated level when compared to all the mature blood cell types studied.
Conclusions: These findings challenge the concept that individual ABC transporters are implicated 
in maintaining stem cell integrity. Instead, a distinct ABC transporter expression signature may be 
essential for stem cell function. The high expression of specific transporters in non-HSCs and mature 
blood cells suggests a specialized, cell type dependent function and warrants further functional 
experiments to determine their exact roles in cellular (patho)physiology.
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BACkground
Controversy has lasted for years regarding the role of ATP-binding cassette (ABC) transporters in 
(cancer) stem cell integrity [1-8]. Early discovery of the relation between ABC transporters and stem 
cells arose from the identification of the “side population” (SP), a stem cell enriched fraction that 
can be isolated based on ABCG2 dependent dye efflux. SP fractions have been observed in both 
hematopoietic and solid tissues [2]. Later, tumor initiating cells were identified in the SP, as indicated 
by ABC transporter gene expression (ABCB1 or ABCG2), chemo-resistance or tumorigenicity in 
vivo [9,10]. Further studies showed that both in solid tumors and in hematological malignancies 
cancer stem cells are intrinsically resistant to a broad range of drugs and exhibit elevated expression 
of drug resistance related ABC transporters including ABCB1, ABCC1 and ABCG2 [11,12]. Notably, 
CD34+CD38- leukemic progenitors, which are ABCB1 and ABCG1 double positive [13], are able to 
repopulate bone marrow in irradiated NOD-SCID mice while the CD34+CD38+ counterparts that 
show a significantly lower expression level of ABCB1 and ABCG1 [13] have no repopulating capacities 
[5,14]. These findings could suggest that ABC transporters contribute to maintain stem cell properties 
of both normal and cancer stem cells. However, mice that lack single ABC transporters show normal 
steady-state hematopoiesis [7]. Also, approaches to enhance cytotoxicity during chemotherapy 
by inhibiting one single transporter have been hardly successful [3]. The knockdown or inhibition 
studies focused on one or a few transporters. As the human gene encodes for 49 ABC transporters, 
functional redundancy may preserve stem cell integrity and chemoresistance following abrogation 
of the function of one or several transporters. 
Recently, we determined the ABC transporter expression signature of hematopoietic stem cells 
(HSCs) [13]. A large set of ABC transporters was highly expressed in both normal and malignant 
HSCs compared to more committed progenitors [13]. Thus, the absence of obvious (stem cell) 
phenotypes following disruption of one or more ABC transporters may be caused by relatively high 
expression of other transporters. In this study we aimed to investigate whether other non-related 
stem cells exert a similar ABC transporter signature as HSCs and profiled transporter expression 
in human non-HSCs including unrestricted somatic stem cells (USSCs), mesenchymal stem cells 
(MSCs), embryonic stem cells (ESCs) and multipotent adult progenitor cells (MAPCs). To compare 
the expression signatures with differentiated cells we also analyzed human mature blood cell types. 
To obtain maximal detection sensitivity over a large range of expression levels, Taqman Low Density 
Arrays (TLDA) were employed to determine gene expression [13,15].
methods
human non-hsCs and mature blood cells 
Human cord blood derived USSCs (n=6) were generated and differentiated towards the osteogenic 
lineage as described [16] [17]. Mature human blood cells were obtained from normal bone marrow 
or peripheral blood by Ficoll gradient centrifugation (granulocytes) or by fluorescence activated 
cell sorting with specific cell surface markers to gain a purity above 95%: CD3+ (T cells), CD56+CD3- 
(NK cells), CD14+ (monocytes), CD71+ (erythroid progenitors) as described previously [18,19]. Total 
mRNA was subsequently isolated using RNABee (Bio-Connect BV, the Netherlands). mRNA of human 
MSCs derived from adult adipose tissue (n=3) and bone marrow (n=4) was kindly provided by Dr. E. 
Piek, Department of Applied Biology and Dr. B. Jansen, Tumor Immunology Laboratory, Radboud 
University Nijmegen Medical Center, the Netherlands [20]. mRNA of human bone marrow derived 
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MAPC lines (n=3) was provided by Dr. C. Verfaillie, Stem Cell Institute, Katholieke Universiteit Leuven. 
The mRNA of three hESC cell lines (HUES1, HES2, and HES3), originating from Douglas Melton’s 
Lab (HUES1) and ES Cell International, Singapore (www. Escellinternational.com) (HES2 and HES3), 
were kindly provided by Prof. Dr. C. Mummery, Department of Anatomy and Embryology, Leiden 
University Medical Centre, the Netherlands. Transporter expression profiles in HSC samples (n=11) 
that we observed earlier [13] were taken as reference for comparisons with the profiles in non-HSCs 
and mature blood cell types.
taqman low density Array
First strand cDNA of the mRNA samples indicated above was synthesized using reverse transcriptase 
as described (Invitrogen) [19].Gene expression profiles were assessed by quantitative real-time 
RT-PCR using micro fluidic cards (Taqman Low Density Arrays, TLDA, Applied Biosystem), covering 
45 transmembrane ABC transporters and three housekeeping genes (GAPDH) as described earlier 
[13]. The expression levels were calculated relative to GAPDH.
statistical analyses
Over 11,000 ABC transporter expression values were generated by TLDA. Some transporter genes 
were expressed at very low levels around the detection limit, introducing unwanted disturbance in 
statistical analyses. To avoid this, the highest mean expression level in the HSCs (6.65E-02, observed 
for ABCA2 in HSCs samples) was divided by 1000 (6.65324E-05) and used as background level. 
Expression values below the background level were replaced by this threshold. In this way the noise 
caused by the variation in extremely low values was abolished. Principal component analysis (PCA) 
[21,22] was performed using Partek Genomic Suite 6.4 to identify outliers in our sample sets and to 
investigate similarities of samples based upon the cell types. Unsupervised hierarchical clustering 
was performed by using Partek Genomic Suite 6.4 to visualize genes defining different cell types 
and to determine the similarity / distance between the studied cell types. We used the Pearson 
dissimilarity as a distance measure. Differential expression was examined by a non-parametric 
Mann-Whitney U-test in Partek Genomic Suite 6.4. Genes with P-values < 0.05 after multiple testing 
correction by bootstrapping were deemed significantly differentially expressed. 
results
non-hsCs show striking similarities in ABC transporter expression profiles 
clearly distinct from hsCs 
Earlier we showed that a broad range of ABC transporters was highly expressed in HSCs compared 
to more committed progenitor cells [13]. To determine the relevance of this finding, we measured by 
TLDA transporter expression profiles in non-HSCs including USSCs, MSCs, MAPCs and ESCs. Striking 
to note is that non-HSCs, regardless their origin, exhibited a remarkable similarity in transporter 
expression clearly distinct from that observed in HSCs (Fig. 1A). Unsupervised hierarchical cluster 
analysis confirmed the strong similarity among non-HSCs. The 11 HSC samples clustered together, 
with a distinguishable distance to other stem cell types (Fig. 1B). MAPCs and ESCs also clustered in 
separate groups while USSCs and MSCs fell into one and the same group, suggesting that MSCs and 
USSCs are closely related (Fig. 1B). Principal component analysis (PCA) verified the resemblance among 
non-HSCs (Fig.1C). Among the HSC samples a larger relative distribution was observed as compared 
to non-HSCs, indicating that differences within HSC samples are greater than those among other 
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stem cells. Another important observation is that most transporters showed higher expression in 
HSCs than in other stem cell types, except for ABCA1, ABCB6, ABCB8 and ABCD3, which were similarly 
expressed in both HSCs and non-HSCs (Fig. 1A). The mean expression values of ABCB1 and ABCG1 
were more than 1000-fold higher in HSCs while the other genes about 10-fold higher. Interestingly, 
some transporter genes, such as ABCA4, ABCA8, ABCC9 and ABCG4, were scarcely detectable in HSC 
samples whereas they were consistently detected in USSCs and MSCs (Fig.1 A and D).
To identify genes representative for each stem cell type, we performed Mann-Whitney U-tests. 
Sixteen genes defined HSCs from non-HSCs (Additional file 1: Genes defining HSCs from other stem 
cells). Amongst these genes some are known to be implicated in hematopoiesis, such as ABCB1 and 
ABCG1 [2,4,5,23]. Notably, ABCB1 is the gene to distinguish HSCs with the highest fold difference in 
median value (1.41E+04 fold). Nevertheless, other transporter genes with no described hematopoietic 
functions, like ABCA3, ABCA5, ABCA7 and ABCD4, also discriminate HSCs from non-HSCs. 
Despite the strong similarity regarding transporter expression in non-HSCs, distinct sets of ABC 
transporter genes could be identified typifying each non-HSC source by Mann-Whitney U-tests 
(Additional file 2: Combination of ABC transporter genes unique for each subgroup of cells). 
Interestingly, some transporters not reportedly related to stem cell functions were significantly 
higher expressed in ESCs compared to other non-HSCs, such as ABCA3, ABCA7 and ABCC8. ABCG2 
figure 1. non-hsCs show striking similarity in ABC transporter expression profiles clearly 
distinct from hsCs. (A) TLDA expression data plot. The expression levels relative to GAPDH 
are shown in log-scale, plotted against the ABC transporter genes ranked in descending 
order by expression levels in 11 CD34+38- HSC samples. The expression profile of CD34+38- 
HSCs here serves as reference [13]. The transporters are further divided into two groups (left 
and right) according to the detection frequency (whether above 10/11) in the HSCs. Count of 
detectable samples out of the 11 reference HSC samples is indicated on the top of the figure for 
each transporter. Transporters genes in the right part are ranked first by detection frequency 
and then by the expression level. The error bars show the standard deviations. In this plot the 
background threshold applied for unsupervised hierarchical clustering and PCA was not used.  
(A)
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figure 1. continued. (B) Unsupervised hierarchical clustering allowing a separation between 
HSCs and non-HSCs based on ABC transporter expression profiles. Red and blue indicate high 
and low expression, respectively.
(B)
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figure 1. continued. (C) PCA of HSCs and non-HSCs based on ABC transporter expression 
profiles verified the resemblance among non-HSCs. This PCA mapping represents 68.1% of 
gene expression information. (D) Detection frequency of each transporter gene in HSCs, 
MSCs and USSCs. 1=100% detection frequency. Note that some transporters are detected in all 
studied USSCs and MSCs but not in HSCs (e.g. ABCA4 and ABCC9).
(D)
(C)
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was differentially higher expressed in the ESC samples we studied and the expression of ABCA8 
and ABCC9 was about 1000-fold lower in ESCs than in other non-HSCs. MAPCs were highlighted 
by ABCA13 with an expression level about 60-fold higher than in other non-HSC sources. MSCs 
also showed differential expression of several transporters while for USSCs only one differentially 
expressed transporter (ABCD4) was observed (Additional file 2). In summary, non-HSCs exhibited 
strikingly similar ABC expression profiles remarkably distinct from those in HSCs and HSC exhibited 
overall higher expression levels compared to non-HSCs. Characteristic sets of transporters in HSCs 
and different non-HSCs were identified, suggesting that specific combinations of transporters are 
important for the physiology of non-related stem cells.
ABC transporters are not down modulated following osteogenic 
differentiation of ussCs
We have shown that ABC transporter expression was downmodulated during the differentiation 
of both normal and leukemic HSCs [13]. Besides, we recently observed that some miRNAs were 
down regulated following osteogenic differentiation of USSCs [17]. These findings prompted us 
to study whether ABC transporter expression decreases following USSC differentiation. However, 
transporter profiling by TLDA did not reveal broad downregulation as observed in the initial steps 
of HSC maturation. On the contrary, some transporters were even induced (Fig. 2). This suggests 
that ABC transporters may serve a different function in USSCs compared to HSCs. 
mature blood cells exhibit higher expression of specific transporters 
compared to hsCs
The substantial expression of a broad range of ABC transporters compared to non-HSCs and 
committed progenitors may indicate that they play an important role in HSC biology. The implication 
figure 2. ABC transporters are not down modulated following osteogenic differentiation of 
ussCs. The expression levels on day 0 are set at 1 and the fold difference in expression at other time 
points is given on day 1, day 3 and day 7. Significant threshold is 3-fold induction or downregulation 
and is indicated by the grey lines. Detection count of each gene in 6 USSC samples is indicated on 
the bottom of the figure for each transporter. Only transporters with detection frequency above 
5/6 in USSCs are included. The error bars represent standard deviation. The genes on the x-axis 
are sorted by expression levels at time point 0 and detection frequency.
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of these transporters in HSC maintenance may be also inferred by their downregulation during 
early steps in HSC differentiation [13]. To study this issue in more detail we measured transporter 
profiles in various mature blood cell types including monocytes, granulocytes, CD71+ erythroid 
progenitors, T cells and NK cells in order to determine whether the high expression is unique to 
HSCs. Unexpectedly, most transporters were expressed at a higher level in at least one of the 
mature blood cell types rather than in HSCs (Fig. 3 A and B). For instance, in T cells, NK cells and 
granulocytes the expression of ABCA7, ABCB2 and ABCB3 was above 10-fold higher than in HSCs. 
The expression of ABCD2 in T cells was evidently elevated in comparison with any other blood 
cell fraction. ABCB1, a gene with widely reported relevance to stem cells, exhibited in NK cells 
an expression level exceeding that in HSCs. Cholesterol transporter ABCA1 and lipid transporter 
ABCA2 were evidently higher expressed in granulocytes and NK cells, respectively, compared to 
HSCs. Likewise, the expression of ABCB6 and ABCB10 and ABCG2 in CD71+ erythroid progenitors 
was more than 40-fold above that in HSCs. The highest expression level of all the studied cell types 
was observed for ABCB10 in CD71+ erythroid progenitors. Unlike other transporters, ABCA13 and 
ABCC1 showed slightly higher expression in HSC samples compared to all mature blood cell types 
(less than 2-fold higher compared to granulocytes and T cells) (Fig. 3 A and B). Consistent with 
the TLDA plots (Fig 3AB), unsupervised hierarchical clustering presented higher expression levels 
mostly in more mature blood cell samples (Fig. 3C). HSC samples fell into a distinct group apart 
from mature blood cell types in both unsupervised clustering and PCA. Characteristic expression 
patterns evidenced by separated clusters were observed for each different mature blood cell fraction 
except for monocytes and granulocytes, which fell into one and the same group in unsupervised 
hierarchical cluster analysis (Fig. 3 C and D). Of note, the CD71+ erythroid progenitor samples 
constituted a tight cluster in PCA, identifying these samples as a highly homogenous and specialized 
cell type (Fig. 3D). Differential gene expression through subgroups of mature blood cell fractions 
was determined by a Mann-Whitney U-test as indicated in additional file 2. Significant differences 
were identified in NK cells and CD71+ erythroid progenitors. ABCB1 was found to represent NK cells; 
so were ABCB6, ABCB10 and ABCG2 representative for erythroid progenitors. 
disCussion
A remarkable finding of this study is that non-HSCs from adult, neonatal or embryonic origins exhibit 
a very similar ABC transporter expression profile that is clearly different from HSCs (Fig. 1 A, B and C). 
Apparently HSCs rely on a different repertoire of transporters whereas for other stem cells it is more 
similar. Three separate clusters can be seen in Fig. 1B for MAPCs, ESCs and USSCs/MSCs, despite the 
strong resemblance regarding transporter expression in non-HSCs. Although USSCs differ from 
MSCs with respect to telomere length, immunophenotype and differentiation potential [16], they 
fell into one and the same cluster in unsupervised hierarchical cluster analysis based on transporter 
expression profiles (Fig. 1B). This indicates a close similarity between USSCs and MSCs. Nevertheless, 
comparison of profiles among non-HSCs revealed differential transporter expression, especially 
for MAPCs and ESCs (Additional file 2). ABCA13 was representative for MAPCs by an expression 
level about 60-fold higher compared to other non-HSC sources. ABCA13 is expressed in human 
hippocampus and cortex and rare variants in this gene have been associated with neurological 
disorders [24]. Since ABCA family members share a cholesterol efflux related C-terminal motif, the 
function of ABCA13 might be lipid related as well [25]. It may explain a role for ABCA13 in neurological 
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(A)
figure 3. mature blood cells exhibit higher expression of specific transporters compared to hsCs. 
(A) (B) TLDA expression data plot. The layout of the plot is as described in the legend of figure 1A.  
(B)
disorders since lipid shuttling across cell membranes is crucial to intracellular signalling pathways 
and neurotransmitter functions. This might imply that MAPCs rely more on lipid metabolic pathways 
than other non-HSCs do. Of note, ABCG2, a transporter of intense debate regarding its expression 
in human ESCs [8,26], was expressed at significantly higher levels in the ESC samples studied here 
compared to other non-HSCs (Fig. 1). This is in agreement with the study of Sarkadi et al [26]. As a 
principal multidrug resistant gene [1,2,4,27-31], ABCG2 can potentially protect undifferentiated ESCs 
against the damage caused by toxins or hypoxia. Specific roles in human disorders or physiological 
functions for several other transporters that are differentially expressed through non-HSC samples 
(Additional file 2) have been reported [32-36]. Further research on their exact function in stem 
cells is warranted.
Another important finding here is that out of the 23 most frequently detected and highly 
expressed transporters in HSCs, the majority showed lower expression in non-HSCs (Fig. 1A). 
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(C)
figure 3. continued. (C) Unsupervised hierarchical clustering of HSCs and mature blood cell 
types based on ABC transporter expression profiles.
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Mann-Whitney U-test revealed 16 transporters to be expressed at significantly higher levels in HSCs 
compared to other stem cells (Additional file 1). Out of these 16 transporters, the expression of ABCB1 
and ABCG1 was above 1000-fold higher in HSCs. The role of ABCB1 in bone marrow repopulation 
capacity and chemoresistance has been intensively studied and widely reported [1,4,5,28,37,38]. 
ABCG1 has been shown to regulate proliferation of hematopoietic stem cells through high-density 
lipoprotein [23,39]. ABCG2, one of the major multidrug transporters [1,2,4,27-31], is not consistently 
detectable in HSCs, which is in agreement with a recent report showing that ABCG2 expression is 
not correlated to hematopoietic progenitor function [6]. On the other hand, some differentially 
expressed genes (above 10-fold higher) have not been reported to have immediate relevance to 
hematopoiesis, such as ABCA3, ABCA5, ABCA7 and ABCD4. These genes might be involved in lipid 
transport or intracellular trafficking of peroxisomes or lysosomes [32-34,40-42]. Lipid redistribution 
is required for polarization of HSCs, which is essential to initiate migration, hence lipid transporters 
(such as ABCA3 and ABCA7) may potentially influence HSC migration [31]. A few transporters, 
including ABCA1, ABCB6, ABCB8 and ABCD3, were similarly expressed in both HSCs and non-HSCs 
but still at a lower level compared to mature blood cell types. Notably, a set of transporters was 
consistently detected in MSCs and USSCs but scarcely detectable in HSCs, including ABCA4, 
ABCA8, ABCC9 and ABCG4 (Fig. 1D). ABCA4, ABCA8 along with ABCG4 might play a role in brain 
lipid transport [42] and ABCC9 constitutes the regulatory subunit of an ATP-sensitive potassium 
channel [43,44]. These four transporters were not significantly expressed in mature blood cell types 
either, representing a specific signature of non-HSCs. 
To further study the relevance of the finding that a broad range of transporters exhibited higher 
expression levels in HSCs compared to non-HSCs we analyzed mature blood cell types. It was observed 
that only ABCA13 and ABCC1 were slightly higher expressed in HSCs than in mature blood cell types. 
As discussed above, ABCA13 might play a role in lipid redistribution [24,25,31]. As HSC polarization is 
(D)
figure 3. continued. (D) PCA of HSCs and mature blood cell types based on ABC transporter 
expression profiles. This PCA mapping represents 80.2% of gene expression information.
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accompanied by redistribution of transmembrane lipid rafts and a polarized morphology is required 
for cells to initiate migration [31], it will be interesting to investigate whether ABCA13 contributes to 
HSC migration. ABCC1 is known to be involved in chemoresistance of hematological cancer stem 
cells [11,12], however it is not obviously downregulated throughout differentiation, questioning its 
contribution to stem cell integrity. Actually most transporters showed evidently higher expression in 
developed blood cell types (Fig. 3 A, B and C), challenging the concept that individual transporters 
may function in maintaining stem cell integrity [1,2,4,5]. For instance, outstanding high expression 
levels were observed for ABCB2 and ABCB3 in granulocytes, T cells and NK cells (Fig. 3 A and B). 
ABCB2 (TAP1) and ABCB3 (TAP2) belong to the transporter associated with antigen processing (TAP) 
family, which is crucial for the adaptive immune system. TAP translocates proteasomal degradation 
products into the endoplasmic reticulum, in order to present them to the major histocompatibility 
complex (MHC) I molecules [45]. This suggests an association of the high expression of ABCB2 and 
ABCB3 with their specific immunological function in T cells and granulocytes. In CD71+ erythroid 
progenitors the expression of ABCB6, ABCB10 and ABCG2 was extremely high in comparison with HSCs 
and other mature blood cell types. These transporters have been implicated in porphyrin transport 
and/or heme biosynthesis, which explains their high expression in haemoglobin synthesizing cells 
[46-51]. Given that mature blood cell types exhibit higher transporter expression compared to HSCs, 
it will be important to compare transporter expression signatures in tissues derived from non-HSCs. 
ConClusions
Here we identified specific ABC transporter expression signature in non-HSCs compared to HSCs. Four 
transporters, ABCA4, ABCA8, ABCC9 and ABCG4, are of special interest since they are expressed in 
non-HSCs but hardly detectable in HSCs or mature blood cells. The high expression of several transporters 
in committed blood cells challenges the concept that individual ABC transporters may maintain stem cell 
integrity by protecting them against xenobiotics [1,2,4,5]. Instead, a distinct ABC transporter expression 
signature might be essential for stem cell function rather than overexpression of single transporters. 
These findings warrant further studies on specific transporters in different cell types.
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Chapter 3 
ABC TRANSPORTER INDUCTION IN LEUKEMIC PATIENTS
ABstrACt
Efflux of cytostatic drugs mediated by ABC transporters has been considered as a major mechanism 
in drug resistance. Prolonged in vitro exposure of cells to cytostatic drugs may enhance drug 
resistance through induction of transporter expression. Whether primary malignant cells upregulate 
transporter expression following drug exposure in vivo is unknown. To study this, leukemic cells 
were isolated from peripheral blood from 10 patients before and during anthracycline and cytarabine 
treatment and profiled for 45 ABC genes. Induction of ABC transporter gene expression was 
observed in all patients. The number of induced transporters varied from 1 to 21. Large differences in 
the kinetics of expression and the fold-induction were observed between patients. In unsupervised 
hierarchical cluster analysis pre- and post-treatment samples from the different patients did not 
cluster in separate groups. In fact, pre- and post-treatment samples from individual patients 
clustered together. Thus, the dynamics in ABC transporter gene expression following treatment 
appears to be tumor cell specific and varies greatly between patients. To test whether induction of 
transporters may contribute to drug evasion, we first studied expression dynamics of 45 ABC genes 
in KG1a cells exposed to leukemia therapy drugs (cytarabine, daunorubicine and mitoxantrone). Up 
to 35 of 45 tested transporters were significantly upregulated (up to 1200-fold) within 24-72 hours 
post treatment, including transporters currently not associated with drug efflux. Functional assays 
showed that the induction of ABCG2 in KG1a cells resulted in enhanced efflux. Thus, KG1a cells may 
protect themselves against cytostatic drugs by upregulating ABC transporter expression during 
drug exposure. Our data may suggest that in addition to pre-treatment ABC activity, differences 
in induction of specific ABC transporters could contribute to drug resistance as well.
key Words:
ABC transporter, leukemia, gene expression, chemotherapy
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BACkground
Acute leukemia is comprised of a heterogeneous group of clonal hematopoietic disorders, resulting 
in disturbed balance of proliferation and differentiation [1-3]. The backbone therapy to recover 
normal hematopoiesis in AML patients by suppressing leukemic cells include cytotoxic drugs such 
as anthracyclines (daunorubicin and mitoxantrone) and cytosine arabinoside (Ara-C) [4,5]. A major 
drawback of the chemotherapy is the development of multidrug resistance (MDR) [6-8]. MDR 
mechanisms include reduced drug uptake, failure of apoptosis, alterations in cell cycle checkpoints, 
increased DNA repair, activation of detoxifying enzymes and, increased efflux of drugs mediated by 
ATP-binding cassette (ABC) transporters [7,9-14]. More than 10 ABC proteins have been implicated 
in an MDR phenotype [8,15] and pre-treatment transporter expression levels can predict therapy 
response [16-18]. It has been indicated that in vitro exposure of cells to cytostatic drugs may enhance 
drug resistance through induction of ABC transporter expression [19]. However, whether ABC 
transporters are induced in cancer cells in vivo during chemotherapy remains unknown. Therefore, 
we determined expression profiles of 45 ABC genes in leukemic cells isolated from patients while 
receiving chemotherapy isolated. We utilized Taqman Low Density Arrays (TLDA) to gain maximal 
detection sensitivity over a large range of expression levels [20,21].
methods
patient samples, cell isolation and culture
KG1a cells were maintained in IMDM supplemented with 10% fetal bovine serum and 1% penicillin/
streptavidine. Cells were exposed to 100 ng/ml mitoxantrone, 100 ng/ml daunorubicin or 10 ng/ml 
Ara-C, respectively. Samples were harvested before and 24, 48 and 72 hours after treatment for 
gene profiling.
For this study, we used surplus material from samples that were taken at the Dept of Hematology 
from the Radboud University Nijmegen Medical Centre for diagnostic purposes from patients who 
were treated for leukemia. We obtained approval from the Radboud University Nijmegen Medical 
Centre Institutional Review Board (RUNMC-IRB) to perform this study. As such, Blood samples 
from 10 patients with different types of hematological malignancies were obtained after informed 
consent at indicated time points during chemotherapy treatment. Mononuclear cells were isolated 
by Ficoll 1077 g/ml gradient and cryopreserved. After collection of all samples the cells were thawed 
and stained with monoclonal antibodies: CD45 to distinguish the major leukocyte population, 
CD34 and leukemia-specific markers (CD10, CD19 and CD117). Leukemic CD34+ cells were sorted 
by Beckman Coulter Epics Altra with Hypersort as described previously [40]. 
taqman low density Array
Total mRNA in KG1a cells was isolated using RNABee (Bio-Connect BV, the Netherlands). From 
leukemic CD34+ blasts total RNA was extracted by using Zymo research Mini RNA isolation II kit 
(Zymo research). First strand cDNA of the mRNA samples indicated above was synthesized using 
reverse transcriptase (Invitrogen). Gene expression profiles following drug exposure were assessed 
by quantitative real-time RT-PCR using micro fluidic cards (Taqman Low Density Arrays, TLDA, 
Applied Biosystem), covering 45 transmembrane ABC transporters and three housekeeping genes 
(GAPDH, HPRT1 and HMBS) as described earlier [21]. The expression levels were calculated relative 
to GAPDH (Supplementary table 1).
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statistical analyses
To avoid the noise caused by the variation in extremely low values around the detection limit, 
expression values below 0.00001 were replaced by this threshold. Unsupervised hierarchical 
clustering was performed by using Partek Genomic Suite 6.4 to determine the similarity / distance 
between the studied samples. We used the Spearman dissimilarity (non-parametric) as a distance 
measure. The intrinsic error of normalized QPCR expression values is about 2-3 CTs. Since Spearman 
dissimilarity analyses are very sensitive to subtle differences in expression values introduced by 
intrinsic errors of QPCR, genes with an overall inter-sample difference (Max/Min) lower than 2 or 
3 CTs were excluded for KG1a cells and patient CD34+ cells, respectively. A lower pre-selection CT 
difference was chosen for KG1a cells because the availability of material allowed us to repeat the 
experiments, reducing the impact of intrinsic error. 
immunodetection of ABC transporter proteins
KG1a cells were exposed to 0.1% DMSO, 100 ng/ml mitoxantrone or 100 ng/ml daunorubicin at a 
density of 2.5 x 105 cells/ml. After 24 hours, 48 hours and 72 hours the cells were harvested and lysed 
in RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% sodiumdeoxycholate, 
5 mM EDTA, protease and phosphatase inhibitors (Roche)), and sample buffer (Invitrogen) 
containing 30 mM dithiothreitol (DTT) was added to the lysates. The lysates were subsequently 
heated for 5 minutes at 95 oC and loaded (10µg) on NuPage Novex Bis-Tris precast 4-12% gradient 
gels (Invitrogen). Proteins were transferred to Immobilon-P PVDF membrane (Millipore). To prevent 
non-specific binding of the antibodies, membranes were blocked with 3% bovine serum albumine 
(BSA) in tris buffered saline containing 0.5% (v/v) tween 20 (TBS-T, pH 7.4) for 1 hour at RT. Following 
blocking, the membranes were incubated overnight with primary antibody (Abcam) and then 
incubated for 1 hour with the appropriate secondary HRP conjugated antibody. The protein bands 
were visualized using an enhanced chemiluminescence-based detection reagent (West Femto) 
and the intensities of the protein bands were determined on a ChemiDoc XRS Imaging system and 
analyzed with Quantity One analysis software (Bio-Rad).
hoechst efflux studies
KG1a cells were cultured in the presence or absence of mitoxantrone (10 ng/ml) or daunorubicin 
(10 ng/ml) for 72 hrs. After exposure cells were washed with phosphate buffered saline and diluted to 
2x105 cells/ml in Iscove’s modified Dulbecco’s medium supplemented with 10% FBS with or without 
Verapamil (75 µg/ml) (Centrafarm, Etten Leur, The Netherlands), as an inhibitor for ABCG2/ABCB1-
mediated transport. The mixture is pre-incubated for 20 min in a water bath at 37 oC. Subsequently 
cells were incubated with 5 µg/ml Hoechst 33342 dye (Sigma Aldrich) for 45 min at 37 oC. Next, 
an efflux for 45 min in Hoechst-free medium was allowed with or without the inhibitor. Cellular 
Hoechst fluorescence was measured on a Beckman Coulter Epics Altra flow cytometer equipped 
with 351 nm UV Enterprise laser type 621CL (Coherent) at 450 nm bp. 
results
patient specific transporter induction patterns following chemotherapy
Prolonged in vitro exposure of cells to cytostatic drugs may enhance drug resistance through induction 
of transporter expression [19]. We tested whether transporters were also upregulated in leukemic cells 
in vivo. A panel of five patients with acute myeloid leukemia (AML), two with chronic myeloid leukemia 
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(CML) in blast crisis, two with myeloid dysplastic syndromes (MDS) with progression to AML and one 
with pro-B-acute lymphoid leukemia (ALL) was studied. Patients received comparable therapy: eight 
patients received anthracyclines in combination with cytarabine, one patient received only cytarabine 
and one patient received anthracyclines but no cytarabine (table 1). ABC transporter expression 
profiles were determined in CD34+ leukemic cells isolated from peripheral blood during therapy at 
different time points. As expected, large differences in expression of ABC transporters was detected 
between the different leukemic cell samples before treatment (Figure 1 and supplementary table 1). 
Notably, during treatment, the total number of upregulated ABC transporters varied widely among 
patients, from 1 to 21 (supplementary table 1). In addition, large differences in the type of transporters 
were observed (Figure 4). Also, the kinetics of and fold-induction differed dramatically among 
leukemic samples. Drug transporters could be exerting continuous induction during therapy in one 
patient and showed a first induction followed by a drop to even below basal levels in another patient 
(supplementary table 1). Induced genes included transporters associated with chemoresistance, such 
as ABCB1, ABCC1 [22,23] and ABCC10 [24,25]. In addition, several transporters (mostly from the ABCA 
and ABCB subfamilies) currently not known to be implicated in the transport of chemotherapeutical 
compounds were also identified to be induced (Figure 1, supplementary table 1). To further analyze 
the transporter signatures, we performed unsupervised hierarchical cluster analysis of the expression 
data (Figure 1). This showed that pre-treatment did not constitute independent clusters. In fact, 
with a few exceptions, pre- and post-treatment samples from individual patients clustered together. 
Although treated samples were separated from the untreated samples for each individual patient in 
cluster analyses, the patient-based clustering indicates that drug induced ABC transporter expression 
is tumor cell specific (Figure 1). Thus, anthracyclines and cytarabine induce ABC transporter expression 
while the dynamics in expression is determined by the tumor. To study this issue in more detail, 
leukemic cells from two patients were treated with daunorubicin and mitoxantrone in vitro. Also in 
the in vitro treated primary samples upregulation of ABC transporters was identified (supplementary 
figure 1). Unsupervised cluster analysis using these samples, also showed patient dependent clustering 
(supplementary figure 1). We conclude that cytostatic drugs induce ABC transporter gene expression 
in leukemic cells in vivo. However, the number of induced transporters, the fold-induction and the 
kinetics in expression are tumor cell dependent. 
table 1. Therapy category of patients. The major drugs used are anthracyclines (represented by A) and cytarabine 
(represented by C).
patient nr type leukemia therapy prognosis
p01 AML-M2 (relapse) A-C+ Poor
p02 Blast Crisis, CML A+C- Poor
p03 AML-M4eo (inv 16) A+C+ Good
p04 AML-M4 (from MDS) A+C+ Poor
p05 Pro-B-ALL (relapse) A+C- Good
p06 AML-M5 A+C+ Good
p07 Blast Crisis, CML A+C+ Poor
p08 AML-M6 A+C+ Poor
p09 AML-M2 or 4 A+C+ Poor
p10 AML (from MDS) A+C+ Poor
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figure 1. patient specific ABC transporter induction shown by unsupervised hierarchical 
cluster analysis. Unsupervised hierarchical clustering was performed based on ABC transporter 
expression profiles in in vivo study. The Red and blue indicate high and low expression, 
respectively. Blood samples were obtained from 10 leukemic patients (7 AML, 2 CML and 1 ALL) 
at different time points (day 0, day 3, day 5 or day 7) during chemotherapy. Samples from the 
same patient clustered together, regardless of chemotherapy or types of leukemia, except 
for one MDS/AML patient (p10). However, for the same patient the samples before and after 
chemotherapy indeed were separated.
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drug- and time-dependent induction of ABC transporters in kg1a cells. 
To test whether induction of transporters may contribute to drug evasion, we first studied 
expression dynamics of 45 ABC genes in KG1a cells exposed to leukemia therapy drugs (cytarabine, 
daunorubicine and mitoxantrone). Before treatment expression of 31 out of 45 transporters was 
detected. Remarkably, as many as 35 of 45 transporters were upregulated following single drug 
exposure (33/45 transporters by mitoxantrone, 35/45 transporters by daunorubicin and 24/45 
transporters by Ara-C) (Figure 1). The fold induction by Ara-C treatment was in general much 
lower compared to that in anthracyclines exposed samples (Figure 2). Of the 14 transporters 
not detected before treatment, 13 became detectable after treatment (Figure 2). Some of the 
induced transporters are known to be involved in the transport of anthracyclines (ABCB1, ABCC2, 
ABCC6 and ABCG2) [26-31] or other chemotherapeutical compounds (ABCB4, ABCB11 and ABCC10) 
[24,25,32-34]. Notably, many transporter genes, which have not been associated with efflux of 
chemotherapeutical compounds so far, were also upregulated (ABCA1, ABCA4-9, ABCC7, ABCC9, 
ABCD1, ABCG4-5 and ABCG8) (Figure 2). The strongest induced transporter in common for all the 
three drugs was ABCC6, albeit its absolute expression levels after induction were still below the 
expression level of several other transporters before treatment. 
Virtually all of the induced transporters already exhibited upregulation 24 hours after treatment. 
Under exposure to mitoxantrone, most transporters peaked at 48 hours to drop at 72 hours to levels 
slightly above that at 24 hours (Figure 1). By contrast, daunorubicin and Ara-C caused a continuous 
increase of transporter expression within 72 hours (Figure 2). Unsupervised hierarchical cluster 
analysis identified differential induction patterns between drugs (Figure 3). Two main independent 
clusters can be seen. One cluster included all Ara-C exposed samples in addition to untreated cells 
and one intermediate time point of daunorubicin. The second cluster contained post-treatment 
time points following mitoxantrone or daunorobicin exposure. Two sub-clusters on the basis of 
drug type were found in the second cluster (Figure 3). This indicates that KG1a cells gain differential 
ABC gene expression signatures following exposure to different drugs. 
upregulation of ABCg2 resulted in enhanced hoechst efflux.
Next we analysed for a few transporters whether RNA expression was in agreement with protein 
levels (Figure 4A). ABCG2 was induced at the RNA and protein levels by both mitoxantrone and 
daunorubicin. ABCC6 RNA expression was induced by both drugs, while protein levels were only 
induced by mitoxantrone. ABCC4 mRNA was downregulated by both drugs but the protein levels 
remained unchanged. Finally, ABCC1 mRNA levels showed little differences and its protein levels 
were also unchanged for daunorubicin while slightly increased following mitoxantrone exposure. 
These data indicate that protein levels do not always mirror RNA levels. Knowing that Hoechst is 
extruded by ABCG2 and that ABCG2 overexpression predicts poor prognostic in the treatment of 
acute myeloid leukemia in vivo [17], we performed efflux experiments to test whether the ABCG2 
protein induction resulted in enhanced efflux. Hoechst efflux by ABCG2 was represented as the 
difference of the intracellular Hoechst fluorescence intensity in the presence and absence of 
the ABCG2/ABCB1 inhibitor Verapamil. A clear increase of Hoechst efflux was observed in both 
daunorubicin and mitoxantrone treated samples (Figure 4B). Thus, the induction of ABCG2 by 
daunorubicin and mitoxantrone results in increased efflux in KG1a cells.
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figure 2. differential ABC transporter induction in kg1a cells by mitoxantrone, daunorubicin 
and Ara-C after 24, 48 and 72 hours. (A) (B) (C) TLDA expression data plot of KG1a cells exposed 
to 100 ng/ml mitoxantrone, 100 ng/ml daunorubicin or 10 ng/ml Ara-C at time point 0 (n=5), 
24 hours, 48 hours and 72 hours (n=2 for each drug). The expression levels relative to GAPDH are 
shown in log-scale, plotted against the ABC transporter genes ranked in descending order by 
expression levels in 5 untreated KG1a cell samples. The transporters are further divided into two 
groups (left and right) according to the detection frequency (whether at 5/5) in KG1a cells prior 
to drug exposure. Count of detectable samples out of the 5 untreated samples is indicated on 
the top of the figure for each transporter. Transporters genes in the right part (low frequency 
part) are ranked first by detection frequency and then by the expression level. The error 
bars show the standard deviations. In this plot the background threshold (0.00001) applied 
for unsupervised hierarchical clustering and PCA was not used. Mitoxantrone/daunorubicin 
induced more dramatic transporter upregulation compared to Ara-C. 
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figure 2. continued. (D) Fold changes in transporter expression in drug exposed KG1a cells. 
Transporter genes are listed in the X-axis and the fold induction is indicated in the Y-axis. Induction 
by mitoxantrone reached a peak at 48 hour. While daunorubicin induced a continuous upregulation. 
The regulation caused by mitoxantrone and daunorubicin was more dramatic than Ara-C.
disCussion
In the samples from10 patients studied, we observed large variation in pre-treatment ABC gene 
expression in line with other gene expression studies [16,35]. Importantly, we observed that ABC 
transporters are upregulated in leukemia cells in vivo in patients that receive anti-leukemia treatment. 
Among the induced genes were transporters that can confer drug resistance but also transporters not 
linked to drug resistance currently (Figure 1 and supplementary table 1). Large variations in the number 
of transporters induced, the kinetics- and fold-difference in expression were observed among the 
patients. Highly induced transporters observed in more than one patient included ABCC3 (in p05, day 
3, above 2000-fold), ABCB8 (in p10, day 3, above 1000-fold), ABCD2 (in p03, day3, above 3000-fold) 
and ABCG8 (in p09, day 7, 167-fold). As observed in KG1a cells, glutathione conjugates transporter 
ABCC6 [30,31] was also dramatically (93-fold) induced in leukemic blasts taken from a patient (p03, 
day 5) treated by Ara-C monotherapy (Supplementary table 1). A recent profiling study [17] revealed 
the overexpression of 6 transporters as poor prognostic factors, including ABCA2, ABCB1, ABCB6, 
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figure 3. unsupervised hierarchical clustering based on ABC transporter expression profiles. 
Mitoxantrone/daunorubicin treated samples constitute one major cluster. The other cluster 
comprises the untreated samples and Ara-C treated samples. This is in agreement with the 
TLDA data described above. The two daunorubicin/mitoxantrone treated samples on the top 
of the sub-figure represent outliers.
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figure 4. Alteration in transporter mrnA level has functional relevance in terms of protein 
level and hoechst efflux. (A) Immunodetection of ABCC1, ABCC4, ABCC6 and ABCG2 proteins in 
KG1a cells cultured with 0.1% DMSO (served as no-drug control), mitoxantrone or daunorubicin 
for 24, 48 and 72 hours. Positive control ß-actin showed equal amount of intensity for each 
sample. The protein of ABCC1 and ABCC4 remained the same after treatment. ABCC6 and 
ABCG2 proteins increased after drug exposure compared to 0.1% DMSO treated samples. This 
is in agreement with the mRNA regulation shown by the TLDA plot in figure 1. (B) Daunorubicin 
and mitoxantrone exposure resulted in increased Hoechst efflux in KG1a cells. KG1a cells were 
exposed to 10 ng/ml mitoxantrone or daunorubicin for 72 hours and then preincubated with 
or without ABCG2/ABCB1 inhibitor verapamil before adding Hoechst. Subsequently efflux in 
Hoechst free medium was allowed and the intracellular Hoechst fluorescence was measured in 
a Beckman Coulter Epics Altra flow cytometer. Hoechst efflux by ABCG2/ABCB1 was depicted 
as the difference between the intracellular Hoechst fluorescence intensity in the presence and 
absence of Verapamil. The efflux in untreated cells is set as baseline efflux and adjusted to 1. The 
efflux in treated samples is represented as a fold change relative to the baseline. Daunorubicin 
and mitoxantrone treated cells exhibited more Hoechst efflux compared to no drug control. 
This is consistent with the TLDA data (Fig. 2) showing increased ABCB1and ABCG2 expression in 
daunorubicin and mitoxantrone exposed KG1a cells.
61
ABC TRANSPORTER INDUCTION IN LEUKEMIC PATIENTS
ABCC13, ABCG1 and ABCG2. All of these 6 transporters were upregulated in the leukemic blasts from 
at least two patients in the samples studied here (ABCC13, ABCG1 and ABCG2 in 2 patients; ABCA2 in 
3 patients; ABCB1 and ABCB6 in 4 patients; see supplementary table 1).
Despite the observed changes in expression following treatment, pre- and post-treatment 
samples did not cluster in two separate groups (Figure 1). In fact, pre- and post-treatment samples 
from individual patients clustered together. In addition, two leukemic blast samples treated in vitro 
with daunorubicin or mitoxantrone, clustered with samples taken from the respective patients 
before receiving treatment (supplementary figure 1). These data indicate that anti-leukemic drugs 
induce ABC gene expression but that the response is tumor-dependent. The differences between 
patients are probably influenced by the genetic make-up of the leukemic blasts. Indeed, large 
differences in pre-treatment ABC gene expression can be observed between different types of 
leukemia but also among specific types of leukemia like for instance AML [16,35]. Several cancer 
genes that are deregulated in leukemia like e.g. p53 and WT-1 regulate ABC transporter gene 
expression [36-39]. The (in)-activation of these transcription factors is thought to cause differential 
pre-treatment ABC gene expression levels [36,39]. Differences in the function of these transcription 
factors may also affect post-treatment regulation of ABC transporter gene expression. In addition, 
naturally occurring polymorphisms in these transcription factors but also polymorphisms in the 
promoters of ABC transporter genes can influence the differential dynamics seen following therapy. 
We used human hematopoietic myeloid progenitor KG1a leukemia cells to determine whether 
ABC transporter induction could be relevant with regard to drug resistances. Many transporters 
were upregulated following drug exposure in these cells. Clear differences in the number of 
induced transporters, the level of induction and the kinetics were observed for cytarabine and the 
anthracyclines daunorubicin and mitoxantrone (Figure 2 and 3). For several transporters tested, 
RNA levels correlated with proteins levels, although this was not always the case. In addition, the 
level of induction at the protein level was more modest compared to differences at the RNA level 
(Figure 4 A). The functional assays on ABCG2 showed that the increase in RNA and protein levels 
resulted in increased efflux function (Figure 4B). Thus, KG1a cells may protect themselves against 
cytostatic drugs by rapid induction of different ABC transporters depending on the type of drug used. 
ConClusions
The fact that cytarabine and anthracyclines induce ABC transporter gene expression in tumor cells 
in vivo could suggest that in addition to pre-treatment ABC expression also differences in induction 
of specific ABC transporters may contribute to drug resistance.
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4MUTATION SCREEN OF ABCB8 AND ABCB10 IN AML PATIENTS
introduCtion
Acute myeloid leukemia (AML) exhibits great heterogeneity in manifestation, sensitivity to therapy 
and genetic basis of pathology. Numerous studies have implied that AML arises from the sequential 
accumulation of mutations at the level of the hematopoietic stem/progenitor cell, resulting in a 
disturbed balance of proliferation, differentiation and apoptosis of immature myeloid progenitors 
[1]. To gain more insight in somatic mutations that affect biological pathways in tumorigenesis, a 
systematic mutation analysis of virtually all annotated human protein coding genes in 11 breast and 
11 colorectal cancers has been performed [2], leading to the identification of 280 genes as candidate 
cancer (CAN) genes. Importantly, several of the identified CAN genes are known to be mutated 
in hematological malignancies, including CBFA2T3 (ETO2), FBXW7, KRAS, NF1, PTEN, RUNX1T1 and 
TP53 [1,2]. Several genes newly identified to be mutated in breast and colorectal cancers belong to 
the class of ATP-binding cassette (ABC) transporters [2], which are known to affect the response 
to therapy of AML and other cancers by conferring chemoresistance. Two of the ABC transporters 
discovered to harbour novel somatic mutations in breast cancer, the mitochondrial transporters 
ABCB8 and ABCB10, are highly expressed in both normal and leukemic haematopoietic stem cells 
[3]. ABCB8 and ABCB10 are structurally closely related and are evolutionary highly conserved, 
suggesting a fundamental function in cellular physiology. Although their function has not been 
completely elucidated, some clues regarding their biological roles can be postulated based on the 
homologues of ABCB10 in other species. Firstly, MDL1 (Multi-Drug resistance Like1), the ABCB10 
homologue from Saccharomyces cerevisiae, regulates cellular responses to oxidative stress, such as 
reactive oxygen species (ROS) [4]. ROS signals stimulate proliferation and induce genetic instability 
in malignant transformed cells, conferring increased basal oxidative stress in cancer cells [5]. ABCB10 
might represent an important factor in mediating the response to oxidative stress in cancer cells. 
Secondly, the murine ABCB10 homologue, ABC-me (ABC-mitochondria erythroid) is a direct target 
of the transcription factor GATA1 and overexpression of murine ABCB10 enhances haemoglobin 
synthesis [6]. Furthermore, a recent study identified ABCB10 to be essential for proliferation of 
human mammary epithelial cells [7]. Thus, mutations in ABCB10 may cause resistance to oxidative 
stress, thereby contributing to cancer development. In this context, we pursued to investigate 
whether ABCB8 and ABCB10 are candidate cancer genes in AML. To this end, the coding region 
of ABCB8 and ABCB10 were screened by heteroduplex analysis (HA) using genomic DNA isolated 
from diagnostic bone marrow or peripheral blood samples from a panel of 94 AML patients who 
were referred to the Department of Hematology at the Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, between 1991 and 2004. 
mAteriAl And method
To identify potential mutations that affect splicing, the first 15 intronic nucleotides surrounding the 
intron-exon junctions were analyzed as well. Amplicons covering relevant regions were generated 
by a two-step polymerase chain reaction (PCR) followed by HA (see table 1 for the sequences of M13 
primers). Fragments exhibiting altered peak patterns in HA were subsequently sequenced to identify 
the nucleotide changes. Exons with multiple known single nucleotide polymorphisms (SNPs) were 
subjected to direct sequencing. A limitation of the HA method is that homozygous mutations or SNPs 
will not be detected. Since all reported somatic mutations in ABCB8 and ABCB10 are heterogeneous 
[2], we reasoned that most point mutations in the cohort would be detected by HA. 
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table 1. Primers used for PCR amplification and sequencing*
gene 
accession
CCds 
accession gene
Coding 
exon forward primer (5’-->3’) reverse primer (5’-->3’)
product 
length **
NC_000007.12 CCDS 5913.1 ABCB8 1 M13f-ttttcaccaatcaccgcca M13r-cgtggactccatctcccg 283
2 M13f-gctggtcagcaggagg M13r-gaatgccatccctttgc 439
      3 M13f-ggatggggaggagtgg    
4
M13r-
gacattacttcaggataaggtcc
469
      5
M13f- 
tctgggggtaggaccttatc
M13r-
ggtgaatccacatgggaaagt
239
6 M13f-aagtccttcctgtcatggtg  
      7   M13r-aagggttggcagggtgtg 504
8 M13f-cacaccctgccaaccctt M13r-ctgctcccagctcctcc 221
      9 M13f-accccaacttgctcttccg M13r-ctggagggcggcagg 300
10 M13f-gcttccttcccctcctctg  
      11   M13r-aatccactcgcctcatccc 494
12 M13f-gcaacaagggctggga  
      13  
M13r-
aagaaaaggcacctgaggact
541
14
M13f-
caccagatagactgtcccattgtg
M13r- 
tgggctgctcactgctcc
300
      15
M13f-
cttagaggatcttgatgggcg
M13r- 
actcattgcagcattgtgcc
409
      16 M13f-ggcattggtttcagagtgtcc M13r-agcgaccacacctcaggg 310
NC_000001.9 CCDS 1580.1 ABCB10 1***      
2
M13f-
gaagcctcctggactcagc
M13r-
agcacatgagatttgagccc
362
      3 M13f-agctgctgcacagtaagtgg M13r-tcagcttgagctcgtctcac 372
4 M13f-acacactcccctttcgtagg M13r-acatcccttaggatctgccc 300
      5 M13f-tcaagagtggctttccattg tctacttatgctgagcaccacag 408
6
M13f-
ggacattacaggccgtgttc
M13r-
cccagttggaataataacattctagg
357
      7 M13f-tctcagaggagtggtggc gggaagagctggtctcattg 237
8 M13f-cccatccatagccagatgag M13r-atctcctagggcgcaaaag 375
      9 M13f-accggatcctttctgtgttg M13r-cccaaagacttccattccttc 269
10
M13f-
aaatcctgttcatggcaaaac
M13r-
agagcaagactcaagactccg
410
      11
M13f-
gaagcttgccttcaaattgc
M13r-
cctccaacaaccttagcacag
375
12
M13f- 
ccaaggctcatccacattg
M13r-
gaattaaaagtgttttggtgaagg
224
      13
M13f-
gctgctgtgtgtatcaggaag
aaagatcttgagaacaggtacgtt 478
* M13 Forward (5’-->3’): tgtaaaacgacggccagt
 M13 Reverse (5’-->3’): caggaaacagctatgacc
** Product length does not include the M13 sequences.
***Exon 1 of ABCB10 was excluded because of large GC rich regions. The start codon starts at the 44th bp in the first 
exon which is 560 bp long. This indicates that 517 nt of ABCB10 coding region were not screened for mutations. 
Mutations reported in ABCB10 are not located in this exon.
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patient materials
Mononuclear cells were derived from peripheral blood (n=30) or bone marrow (n=64) obtained 
from 94 patients with acute myeloid leukemia at diagnosis and 50 healthy controls after informed 
consent was obtained. Genomic DNA was isolated using the NucleoSpin Blood kit (Macherey-Nagel 
GmbH & Co.KG, Düren, Germany).
two-step pCr 
Primers were designed using ExonPrimer (http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.
html). Primer sequences are listed in supplemental table S1. The first PCR was used to introduce 
M13 forward and reverse sequences to both ends of the target amplicons (Fig. 1). Reaction were 
carried out in a 10 µl volume containing 0.25U AmpliTaq Gold DNA polymerase (Applied Biosystems), 
1xTaqman Buffer A (Applied Biosystems), 1.5 mM MgCl
2
 (Applied Biosystems), 0.25 mM dNTP 
(Amersham Biosciences, USA), 0.3 pmol/µl forward primer, 0.3 pmol/µl reverse primer and 40 ng of 
genomic DNA. PCR conditions comprised an initial denaturing step of 5 minutes at 95 ºC, and then 
an amplification loop repeated for 40 times comprising 30 seconds at 95 ºC, 1 minute at 55 or 60 ºC 
and 1 minute at 72 ºC, followed by a final extension step of 10 minutes at 72 ºC. Subsequently, 0.4 µl 
of the product from the first PCR was used as template in a second PCR to introduce 6-carboxy-
fluorescine (FAM)-labelled M13 forward primer sequences (Fig. 1). The reaction was performed with 
similar PCR conditions. After agarose gel examination, the second PCR products were purified by 
MultiScreen 96-well filter plates (Millipore Corporation, USA).
heteroduplex analysis
Using a DNA Analyzer (ABI-PRISM 3730, an Applied Biosystems), mobility differences of hetero- and 
homoduplexes were detected in capillary array electrophoresis (Fig. 1). Signals were analyzed by 
GeneMapper V4.0 software (Applied Biosystems) (Fig. 2). The mixture subjected to HA contained 5 µl 
of LIZ500+ marker and a proper amount of purified second PCR product in a final volume of 10 µl. 
Samples that showed aberrant heteroduplex peaks (see Fig. 2 for an example) were subsequently 
sequenced by M13 forward and reverse primers (see table 1 for the sequences of M13 primers).
t-cells expansion from cryopreserved samples
To culture T-cells from cryopreserved peripheral blood or bone marrow samples, thawed cells 
were incubated for 30 min to let (monocytic) cells adhere. Non-adherent cells were subsequently 
cultured in IMDM (Invitrogen) supplied with 1% penicillin/streptomycin and 10% human serum. 
T cell expansion was initiated by IL-2 addition (every 2 days, from day 1, 100 U/ml) and CD3/CD28 
Dynabead stimulation (Invitrogen) according to the manufacturer’s instruction. Cells were diluted 
to 0.5x106/ml during each subculture. The purity of T cells was examined by four colour FACS 
analysis (CD45, CD3, CD4 and CD8 staining). CD3 positive cells were sorted by FACS to achieve a 
purity above 98%. Genomic DNA of purified T cells was isolated using the QIAamp DNA blood Mini 
Kit (QIAGEN, the Netherlands).
results And disCussion
A total of 0.85 Mb of tumor genomic DNA, spanning exons 1-16 of ABCB8 and exons 2-13 of ABCB10, 
was analyzed (summarized in Fig. 3). To ensure that putative mutations were not PCR or sequence 
artefacts, amplicons containing nucleotide changes were re-amplified and resequenced in the 
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figure 1. principle of heteroduplex analysis. (A) The primers are searched with a minimal 
distance of 50bp from the exon/intron boundary. An universal M13 forward or reverse primer 
(in red) was added to the 5’end of each primer. (B) In the first PCR untagged amplicons with M13 
forward and reverse overhangs were generated. In the second PCR the forward primer is replaced 
with a FAM (in yellow)-labelled M13 forward primer. Thus, the final PCR product is labelled by 
FAM. (C) Explains the formation of heteroduplexes in the presence of a heterogeneous point 
mutation. The heteroduplex and the homoduplex exhibit different electrophoresis motility 
pattern in HA screens.
corresponding patient samples. This led to the identification of 8 new single base substitutions and 
4 described SNPs across the ABCB8 coding region together with 1 new single base substitutions 
and 2 known SNPs in the ABCB10 coding sequences with different frequencies among the studied 
cohort (Fig. 4 and table 2). In ABCB8, 4 of the 8 new nucleotide changes predicted amino acid 
substitutions, distributed in both conserved (transmembrane domain) and non-conserved domains. 
The remaining 4 variants did not result in amino acid changes (Fig. 4 A). The variant in ABCB10 led 
to an amino acid substitution in the transmembrane domain as indicated in Fig. 4B. The reported 
(A)
(B)
(C)
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figure 2. example of heteroduplex analysis results. (A) GeneMapper V4.0 interface of HA analysis. 
The upper panel shows a single normal peak (in blue) and the lower panel shows a heterogenous 
SNP (intron 4 -118 A>G, relative ABCB10 genomic location 17826) peak pattern (in blue). The LIZ500+ 
marker is in yellow. (B) Demonstrates the sequence result of the fragment indicated in the lower 
panel in panel A. The mutation T to A mutation is indicated with a vertical arrow.
(A)
(B)
polymorphisms (GenBank) in the coding region of ABCB8 include 7 non-synonymous and 3 
synonymous SNPs (Fig. 4A); while in the ABCB10 coding sequences 4 missense and 4 silent SNPs have 
been described in GenBank (Fig. 4B). No new changes were observed within 15 base pairs from the 
exon-intron boundaries (table 2). The 8 new variants in ABCB8 and the one in ABCB10 were further 
analyzed to distinguish between somatic mutations and new germ line variants / polymorphisms. 
Therefore, the newly discovered nucleotide changes were tested in matched remission samples or 
in T-cells cultured from cryopreserved peripheral blood from the corresponding patients. A total 
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figure 3. schematic diagram of mutation discovery screen and somatic mutation evaluation. 
The counts of new variant and polymorphism shown in this figure represent single mutation/ 
polymorphism events (number of patients carrying each variant) but NOT unique types of 
variants. The observed frequency of SNPs were compared with reference frequency from 
GenBank by CRITBINOM analysis. 
of 50 unrelated healthy controls were screened by direct sequencing when remission material was 
not available to determine whether putative mutations represented novel polymorphisms. Eight 
out of these 9 new variants were present in control samples or T-cells and were hence considered 
to represent germ line variants or new polymorphisms (Fig. 4). The remaining putative mutation 
(c.1572 C>T, G493G) that is located in the coding region of ABCB8 was not further analyzed since 
it was silent and remission material and cryopreserved material from this case was not available. 
Based on these results we exclude ABCB8 and ABCB10 as cancer genes in AML.
ConClusion
In combination with the known polymorphisms, a total of 19 variants in the ABCB8 coding region 
and 9 in ABCB10 are present (Fig. 4). It is reported that functional SNPs and haplotypes in ABC 
transporter genes may contribute to cancer susceptibility or prognosis [8]. None but one non-
synonymous SNP (c.1003 C>T, R304C, ABCB8) detected in our patient cohort had a significantly 
different frequency (0.123) from that reported (0.339). Therefore, it is interesting to study this finding 
in independent cohorts of AML patients and controls. The restrained variation in ABCB10 compared 
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table 2 A. Observed new variants*
gene exon
new 
variant known (y/n) AA change
number of patients number of controls
Wt het hom Wt het hom
ABCB8 exon 2 C5457G n L124V 73 2 0 49 0 0
  exon 2 C5217T n R44W 74 1 0 49 0 0
  exon 3 C5916T n V158V 71 1 0 49 1 0
  intron 5 G7121A n no cahnge 82 2 0 47 3 0
  exon 6 G7215A n S274S 74 1 0 50 0 0
  exon 7 G7515A n R328H 74 0 1 50 0 0
  intron 7 G7606A n no change 75 8 1 N.A.**  
  intron 8 T7762C n no change 74 9 1 N.A.  
  intron 8 C8025T n no change 76 1 0 N.A.    
  intron 10 G11923T n no change 76 1 0 N.A.    
  exon 12 C12496T n G493G 73 1 0 50 0 0
  intron 12 C12516G n no change 73 1 0 50 0 0
  intron 12 C12563G n no change 73 1 0 50 0 0
  exon 16 A16879C n P703P 74 5 0 50 2 0
  exon 16 G16899T n G710V 71 7 1 50 4 0
ABCB10 exon 3 C11156T n L254F 82 1 0 N.A.    
  intron 4 A17826G n no change 83 1 0 N.A.    
table 2 B. Observed SNPs*
gene exon snp known AA change
number of patients number of controls
Wt het hom Wt het hom
ABCB8 intron 1 A213C y no change 39 37 8      
  exon 2 G5490A y V135I 70 5 0 47 2 0
  intron 2 G5829C y no change 13 34 25 14 18 18
  intron 4 C6189T y no change 57 15 0 37 12 1
  exon 6 C7303T y R304C 68 7 2 47 3 0
  exon 7 T7516A y R328R 45 25 5 21 22 7
  intron 10 C12038T y no change 73 4 0      
  intron 12 12613insGG y no change 57 17 0 37 13 0
  exon 14 G13545A y V542I 77 5 0 43 1 0
ABCB10 intron 2 G9521A y   76 1 0 N.A.    
  ex 3 C11179T y S301S 55 28 0 N.A.    
  ex 8 G28485A y N545D 81 2 0 N.A.    
  intron 8 A28514G y   82 1 0 N.A.    
  intron 11 T37213G y   54 25 0 N.A.    
* The positions of new variants and SNPs are relative to the genomic sequences of gene ABCB8 or ABCB10. 
Reference accession number of ABCB8: NC_000007.12; Reference accession number of ABCB10: NC_000001.9.
**N.A. represents not assessed.
WT: wild type
HET: heterozygous
HOM: homozygous
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figure 4. location of nucleotide changes observed in ABCB8 and ABCB10 in 94 Aml patients 
compared with genBank sequences. The conserved domains (transmembrane and ATP 
binding domains) and segments of low compositional complexity (empty blocks) are depicted 
in the schematic representation of the two transporters. The upper panels of the two schematic 
diagrams show the variants identified in our patient cohort; the lower panels show the previously 
described SNPs not found in our patient cohort. Newly discovered genetic variants and SNPs 
are indicated by their positions at the cDNA level. The filled and empty circles represent new 
and known SNPs, respectively. The frequency of each variant in our cohort is indicated by the 
number of patients who carried that variant. (A) Variants observed in the ABCB8 coding region. 
Three new variants were also present in healthy controls: c.567 C>T (V158V, n=1, heterozygous), 
c.2202 A>C (P703P, n=5, heterozygous) and c.2222 G>T (G710V, n=8, one homozygous and seven 
heterozygous). Two new variants were found in remission samples: c.1076 G>A (R328H, n=1, 
homozygous) and c.463 C>G (L124V, n=2, heterozygous, present in the remission sample of one 
(A)
(B)
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to ABCB8 might suggest that the former protein has a more conserved function. Despite the fact 
that significant overlap between genes mutated in solid tumors and hematological cancers has 
been identified [1,2], this study shows that the ABCB8 and ABCB10 genes found to be CAN genes 
in breast cancer are not mutated in acute myeloid leukemia.
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5ABCB10 IN ERYTHROPOIESIS
introduCtion
Terminal erythroid differentiation requires increased mitochondrial iron uptake and processing 
directed toward maximizing haemoglobin synthesis for oxygen delivery by mature red blood 
cells [1]. We have recently identified the mitochondrial ATP-binding cassette (ABC) transporters 
ABCB6,-7,-8 and -10 to be highly expressed in CD71+ erythroid progenitor cells compared to other 
human hematopoietic subsets [2]. Several mitochondrial transporters have been described to play 
a role in the biosynthesis and transport of haem and FeS clusters. ABCB6 imports porphyrins into 
mitochondria and up-regulates de novo porphyrin synthesis. Its overexpression increases cytosolic 
haem and protects cells against oxidative stress, whereas suppression of ABCB6 reversed these 
phenotypes [3]. ABCB7 is a FeS cluster exporter and mutations in this gene cause X-linked sideroblastic 
anemia with ataxia (XLSA/A) due to mitochondrial iron overload [4]. ABCB10 is located in the inner 
mitochondrial membrane, with its ATP-binding cassette directed into the mitochondrial matrix 
[5,6]. During murine red cell development, Abcb10 gene expression is strongly induced by GATA-1 
and forced Abcb10 expression in differentiated MEL cells enhances haemoglobin formation [6]. In 
agreement, we recently observed that ABCB10 is the most highly expressed transporter in CD71+ 
erythroid precursors [2]. However, whether ABCB10 is required for human erythroid development 
remains unclear. To this end, we employed the pLenti/u6 Block-it system (Invitrogen) to generate 
lentiviruses expressing shRNAs targeting ABCB10. The blasticidin resistant gene was replaced by 
the truncated nerve growth factor receptor (dNGFR) to enable FACS sorting of transduced cells. 
mAteriAl And methods
shrnA design and lentiviral production 
The pLenti/u6 Block-it system (Invitrogen, Life Technologies Europe BV, Bleiswijk, The Netherlands) 
was used to generate lentiviruses expressing shRNA’s targeting ABCB10 as instructed by the 
manufacturer. The blasticidin resistant gene in the original destination vector was replaced by the 
truncated nerve growth factor receptor (dNGFR) selection marker to enable FACS analysis and cell 
sorting [7]. Viruses were produced in basic expansion medium without serum to facilitate stem cell 
growth during transduction (by replacing Opti-MEM medium by basic stem cell expansion medium 
16 hours after lentiviral vector transfection in 293 FT producer cells). The shRNA’s were designed 
with BLOCK-iT™ RNAi Designer as the following:
shRNA-A:  5’-CACCGCAGGAGGTTGCTTTCTTTGACGAATCAAAGAAAGCAACCTCCTGC-3’
shRNA-B:  5’-CACCGCACAGGAGAATTGATTAACCCGAAGGTTAATCAATTCTCCTGTGC-3’
Scrambled control A:  5’-CACCGCCATGCCTGCATTCTTCATCGAAATGAAGAATGCAGGCATGG-3’
Scrambled control B:  5’-CACCGCATGGATCGTCTTGGTTTCGAAAAACCAAGACGATCCATGC-3’
When performing transduction, equal amount of viruses containing ABCB10 shRNA-A and 
shRNA-B were combined to obtain more efficient gene knockdown (data not shown). Scrambled 
shRNA-A or B was used as controls.
Knockdown at mRNA level was examined by QPCR and ABCB10 protein expression was detected 
by Western blotting (Abc-me antibody, Santa Cruz) using isolated mitochondria.
mitochondria isolation and Western blotting
Mitochondria of K562 cells were isolated by Mitochondria isolation kit of cultured cells (Thermo 
Scientific) according to the manufacturer’s instruction. Mitochondria pellets were dissolved in PBS 
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with 2% β-lauryl maltoside (Sigma) and then denatured by Tricine sample buffer (Bio-Rad) with 2% 
β-Mercaptoethanol (Merck) at room temperature for 1 hour. 75 µg of mitochondria membrane 
protein was used for each cell line to run SDS-PAGE gel. 1:500 dilution of ABCB10 antibody (Abc-me, 
Santa Cruz Biotechnology) was used in Western blotting. Antibody against mitochondrial complex 
IV (Cox-I, MitoSciences) was used as loading control.
erythroid differentiation of k562 cells
Erythroid leukaemic K562 cells were transduced in retronectin (120 µg/ml) coated dishes and sorted by 
MACS (Miltenyi Biotech) using dNGFR antibodies [7] and secondary Goat anti-Mouse IgG microbeads, 
(Meltenyi Biotech). 20 ng/ml Ara-C was added at a cell density of 50,000 cells/ml to trigger erythroid 
differentiation. After 4 days of treatment K562 cells were lysed and stained by Tetramethyl benzidine 
(TMB) for haemoglobin quantification as described before [8]. The erythroid markers CD71 and 
Glycophorin-A (GPA) were examined by FACS using monoclonal antibodies (CD71-FITC, Dako; GPA-
PE-Cy5, Beck and Dickinson). Alterations in globins and haem were validated by HPLC.
isolation and culture of human Cd34+ hematopoietic cells
Primary human CD34+ hematopoietic stem/progenitor cells were isolated from GCS-F mobilized 
peripheral blood mononuclear cells using anti-CD34 immunomagnetic beads (Miltenyi Biotech) 
according to the manufacturer’s instruction. Cells were subsequently prestimulated for 1 day prior 
to lentiviral transduction in glycol stem basic expansion medium (Glycostem) supplemented with 
10% human sera, 50 ng/ml Rh-Flt3L, 10 ng/ml Rh-TPO, 50 ng/ml Rh-SCF and 40 ng/ml Rh-IL3. Cell 
density was maintained within 50-150,000 cells/ml during prestimulation. Lentiviral transduction 
was performed by mixing virus sup with equal volume of 2x concentrated expansion medium 
described above with 8 µg/ml polybrene for 24 hours.
Colony- forming unit (Cfu) assays of human Cd34+ cells
GCS-F mobilized primary human CD34+ cells were isolated using anti-CD34 immunomagnetic beads 
(Miltenyi Biotec). Following prestimulation cells were lentivirally transduced and subsequently sorted 
by FACS (Beckman Coulter Epics Elite) based on CD34 (FITC) and dNGFR expression. 1000 sorted 
cells were directly seeded into 1 ml methylcellulose (HSC-CFU complete with Epo, Miltenyi Biotec) 
for CFU assays. Red and white colonies were counted 10 – 14 days after seeding. Subsequently, cells 
were May-Grünwald-Giemsa (MGG) stained for morphological analyses.
results And disCussion
We silenced ABCB10 in erythroid leukaemia K562 cells. Lentiviral gene silencing resulted in 
approximately 90% knockdown at mRNA level compared to scrambled controls. In line with this, 
a strong reduction (>75%) of ABCB10 protein expression was observed following shRNA silencing 
(Figure 1A and B). Following Ara-C induced erythoid differentiation, both ABCB10 silenced and 
control cells upregulated their ABCB10 gene expression, although the gene knockdown cells 
did so to a much lower extent (Figure 1C). Expression of the erythroid markers CD71 and GPA 
was comparable between ABCB10 silenced and control cells (data not shown). However, after 
Ara-C treatment CD71 and GPA were induced to a larger extent in control cells compared to their 
ABCB10 silenced counterparts (Figure 1D). Importantly, ABCB10 silenced cells contained less than 
50% haemoglobin 4 days after Ara-C treatment compared to control cells, which could also be 
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figure 1. ABCB10 knockdown decreases haemoglobinization during erythroid differentiation 
of k562 cells. (A) ABCB10 expression in K562 cells (n=4). mRNA expression was measured by QPCR 
relative to GAPDH. The expression in scrambled controls was adjusted to 1 and the expression levels 
in cells transduced with ABCB10 shRNA’s were presented as relative fold change. The error bars 
represent the standard deviation. About 90% knockdown at mRNA level was achieved by ABCB10 
shRNA’s (for sequences see supplementary methods). (B) ABCB10 protein is reduced in ABCB10 
silenced cells compared to scrambled control cells. Mitochondrial inner membrane protein 
Complex IV (COX-I) was used as loading control. The ABCB10 protein level was corrected based on 
intensity of the loading control in ABCB10 silenced cells versus control cells. After compensation, 
76% knockdown was shown in ABCB10 shRNA silenced cells compared to scrambled controls. (C) 
Ara-C regulated ABCB10 expression measured by QPCR (n=3). Expression in untreated scrambled 
controls was adjusted to 1. The expression in other samples was represented as relative fold 
change. The knockdown in ABCB10 shRNA transduced cells remained after Ara-C treatment. (D) 
FACS analysis of CD71 and GPA (n=3). Y axis represents the fold change of mean fluorescence 
intensity relative to day 0. ABCB10 knockdown cells upregulated erythroid markers CD71 and GPA 
to a lower extent compared to controls upon Ara-C treatment. * indicates significant difference 
(P = 0.031). (E) TMB staining of haemoglobin in differentiating K562 cells (n=3). Optical density 
(OD) at 600 nm was measured spectrophotometrically. In each differentiation assay the OD value 
in control cells before treatment was set as 1. The haemoglobinization in cells transduced with 
ABCB10 shRNA’s was presented as relative fold change. The error bars represent the standard 
deviation. * indicates significant difference (P = 0.039). 
(A) (B) (C)
(D) (E)
visualized by the colouration of cell pellets (Figure 1E and F). Reverse phase HPLC performed on 
lysates isolated from differentiated cells confirmed the reduced formation of both haem and globins 
upon ABCB10 knockdown (Figure 1G and H).
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figure 1. continued. (F) Decrease of haemoglobinization shown by collecting K562 cells. In each 
eppendorf tube 2 million cells were pelleted. Undifferentiated cells showed white pellets. The 
control cells exhibited a red pellet while the knockdown cells gave an orange pellet. (G) and (H) 
HPLC analysis showed reduced haem and globins in ABCB10 silenced K562 cells (H) compared 
to scrambled control (G). The separation by reversed phase HPLC of the globin chains was 
performed with an AKTA purifier 100 HPLC (GE Healthcare) with a sample injector and a variable 
UV detector operating at 215 nm according to manufacturer’s instructions. The column used 
was a VWR LiChrospher 100 RP-8 and elution was obtained in a linear gradient during 25 column 
volumes of solvent A and B with a flow rate of 0.8 ml/min. The gradient started with 25% solvent 
B  ( acetonitrile 100% HPLC-grade, methanol 100% HPLC-grade, 0.155 M NaCl mixed in ratio 
68:4:28) and 75% solvent A (acetonitrile 100% HPLC-grade, methanol 100% HPLC-grade, 0.077 
M NaCl mixed in ratio 26:33:41) and subsequent elution with 50% solvent B and 50% solvent A.
(F)
(G) (H)
To determine the relevance of disturbed differentiation and haemoglobinization observed in 
the K562 cell line following ABCB10 silencing, we analyzed whether ABCB10 knockdown also affected 
erythroid development of primary human hematopoietic cells. To study this, we performed colony 
forming unit (CFU) assays using primary human CD34+ cells following transduction with scrambled 
and ABCB10 silencing constructs. Strikingly, in CFU assays, red colony numbers declined dramatically 
(about 80%) in ABCB10 shRNA cultures compared to scrambled controls (Figure 2A). ABCB10 silencing 
also resulted in smaller red colonies and lack of efficient burst-forming-unit erythroid formation 
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figure 2. ABCB10 silencing dramatically inhibited red colony formation of human Cd34+ cells. (A) 
Absolute number of colonies from 3 donors, scored between day 10 -14. 1000 transduced CD34+ 
cells were sorted into methylcellulose supplemented with 3 U/mL erythropoietin in a 6-well plate 
[12]. The error bars represent the standard deviation of the colony numbers. The red colony numbers 
in the wells following ABCB10 silencing were decreased about 80% compared to scrambled controls. 
However, the white colony numbers were significantly increased upon ABCB10 knockdown (130%). 
(B) (C) Representative cytospins of cells harvested from CFU assays followed by MGG staining. In the 
scrambled control slide (B) orthoerythroblasts (blue arrow), proerythroblasts (orange arrow) and 
enucleated erythroid cells (red arrow) can be seen. In the ABCB10 knockdown slide (C) erythroid 
cells can be hardly found. (D) MGG scoring of cytospins from two donors.
(A)
(B) (C)
(D)
85
ABCB10 IN ERYTHROPOIESIS
figure 3. ABCB10 silencing results in decreased size of red colonies and lack of efficient 
Bfu-e formation. Representative pictures were taken at a 100X magnification on day 11 of the 
CFU assays. Efficient BFU-E formation was observed in the scrambled controls. For the dishes 
with ABCB10 silenced cells both the size and intensity of red colour were reduced. Efficient 
BFU-E formation was also lacking.
(Figure 3). Forced expression of mouse Abcb10 has been shown to enhance haem synthesis in 
differentiated MEL cells through interactions with the iron importer mitoferrin-1 and the haem 
synthesizing enzyme ferrochelatase [9,10]. To study at what stage ABCB10 is required for red blood 
cell development we analyzed by May-Grünwald-Giemsa (MGG) staining the morphology of the 
cultured cells from the CFU assays. Analysis of control transduced cells showed various maturation 
stages of red blood cells including ortho-erythroblasts, pro-erythroblasts as well as enucleated 
erythroid cells (Figure 2B and D). However, following ABCB10 knockdown a dramatic decrease of 
all differentiation stages along the erythroid lineage was found (Figure 2C and D). This indicates 
that ABCB10 is required at early stages of red blood cell development. This finding is in agreement 
with a recent study demonstrating very high ABCB10 expression in erythroid colony forming cells 
and even higher expression at the pro- and intermediate erythroblast stages followed by a sharp 
decrease in expression at the late erythroblast stage [11]. Together, these data suggest that ABCB10 
may exert functions early during differentiation that may not be related to Mfrn1 stabilization [9-11]. 
In line with this assumption, we consistently observed a significant increase in the number of white 
colonies (130%) following ABCB10 knockdown in the CFU assays (Figure 2A), although their size 
was comparable to control transduced clones. How the decrease in red colonies and the increase 
in white colonies are brought about remains to be studied. It could be possible that ABCB10 inhibits 
the clonogenic capacity of granulocyte-macrophage progenitors. ABCB10 knockdown could then 
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explain the increase in white colony numbers. Alternatively, progenitor cells directed towards 
erythroid development may depend on ABCB10 and its absence may result in redirecting cells to 
differentiate along the granulocytic/monocytic lineage. This does not necessarily imply that ABCB10 
is an active driver for erythroid differentiation. Indeed, earlier published work displayed that forced 
expression of mouse Abcb10 does not trigger spontaneous differentiation of MEL cells [6]. 
To understand how ABCB10 contributes to blood cells development, it will be interesting to 
identify its substrates. This work adds ABCB10 to a growing list of mitochondrial transporters (like 
ABCB6 [3] and ABCB7 [4]) important for proper red blood cell development.
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A unique repertoire of ABC transporters is expressed in various stem cells:  
is the physiological role of ABC transporters in stem cells protection  
or preserving stemness?
ABC transporters are thought to preserve stem cell integrity not only by protecting cells against 
damaging agents, but also by effluxing substances that induce differentiation. The latter assumption 
is characterized by the identification of the “side population”: a stem-cell-enriched fraction that 
can be isolated based on ABC (ABCG2 and ABCB1) transporter-dependent dye efflux. We previously 
showed that a broad range of transporters are expressed in HSCs [1], indicating that even more 
transporters might be implicated in stem cellness. When we compared the expression profile of 
45 transporters in HSCs and non-HSCs, including USSCs, MSCs, MAPCs and ESCs, and in more 
differentiated blood cells such as CD71+ erythroid progenitors, NK cells and T cells [2], HSCs turned 
out to possess a distinct transporter expression signature. This was characterized by a generally 
higher level of expression than is found in other stem cells. 
The unrelated non-HSCs exhibited a remarkable similarity in transporter expression. HSCs 
apparently rely on a more divergent repertoire of transporters than other stem cells. The ABC 
genes [2] (Chapter 2, additional file 2) that distinguish HSCs from other stem cells include several 
transporters involved in drug efflux, such as ABCA3 [3] [4,5], ABCB1, ABCC1,5,10 and ABCA2 [6] 
[7]. Interestingly, ABCA3 is also involved in hematopoietic stem cell expansion [8,9]. This set 
of transporters is highly expressed in HSCs, which could reflect the lifelong need to protect 
hematopoietic cells in order to replenish various functional blood cells. In addition, several elegant 
studies have shown that ABCG2 -/-, ABCC1-/- and ABCC1/ABCB1 double knockout mice demonstrate 
enhanced sensitivity to chemotherapeutics, while still possessing normal steady state hematopoiesis 
[10]. This actually indicates a role for transporters in protection of HSCs rather than preserving 
the stemness of these cells. This hypothesis is supported by our gene profiling study on HSCs 
and mature blood cells as well as committed progenitors [2] which demonstrated that almost all 
transporter genes examined were expressed at higher levels in at least one type of mature blood 
cell when compared to HSCs. This challenged the previous notion that high transporter expression 
could be a stem cell property [10-12]. The transporter knockout studies in mouse models also cast 
doubt on the need for transporters in stemness maintenance [10]. In line with this suggestion, drug 
transporter ABCA3 was shown to be activated by SALL4, a robust stimulator for hematopoietic 
(leukemic and otherwise) stem cell expansion [4,5] [8,9], which indicates enhanced protection 
of stem cells during proliferation. Thus, it is worthy to investigate whether more transporters are 
activated upon proliferation under both physiological and pathological conditions.
In fact, the transporters that were expressed at elevated levels in mature blood cells have been 
related to cell-type-specific functions. For instance, we observed high expression of ABCB2 (TAP1) 
and ABCB3 (TAP2) in monocytes, T cells, NK cells and granulocytes. TAP molecules constitute a 
key MHC class I-mediated cellular immune defense against infected or malignantly transformed 
cells [13]. In CD71+ erythroid progenitor cells, ABCG2 and ABCB5-10 exhibit considerably higher 
expression than in HSCs. Most of the erythroid-specific transporters are implicated in porphyrin 
transport or heme synthesis. ABCG2 enhances hypoxic cell survival through interactions with heme 
and it has been recently identified as a transporter for heme and porphyrin [14-18]. ABCB6 imports 
porphyrins into mitochondria and upregulates de novo porphyrin synthesis [15,19]. ABCB7 is an FeS 
cluster exporter, and mutations in this gene cause X-linked sideroblastic anemia with ataxia (XLSA/A) 
due to mitochondrial iron overload [20,21]. ABCB8 is implicated in mitochondrial iron export [22]. 
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Both ABCB7 [23] and ABCB10 [24,25] interact with ferrochelatase, an enzyme that catalyzes the 
terminal step in heme synthesis, converting protoporphyrin IX into heme. Furthermore, ABCB10 
stabilizes mitochondrial iron importer mitoferrin-1 through the formation of a ferrochelatase-
ABCB10-mitoferrin-1 complex and therefore enhances heme synthesis [24,25]. Taken together, the 
identification of certain transporters as stem cell markers does not exclude the possibility of their 
high expression in specialized tissue cells, where they may exert functions other than xenobiotic 
efflux that are required for the survival and physiology of the particular cell type. Future research 
on cell type dependent transporter function may reveal more aspects of their physiological roles. 
deregulation of ABC transporters in cancer-initiating cells: implications  
for drug sensitivity and acquired self-renewal 
Cancer stem cells may originate from regular stem cells that transform into cancer-initiating cells, 
but also from more mature cells, which become cancer-initiating cells by acquiring self-renewal 
properties [26]. Depending on the tissue of origin, tumor stem cell survival is associated with elevated 
expression of specific sets of ABC transporters, compared to their more differentiated progeny 
[7,9,26-29]. The overexpression of ABC transporters in cancer stem cells might favor the retention of an 
undifferentiated state [6]. ABCG5 is a putative stem cell marker for solid tumors [28]. Its expression has 
been correlated with melanoma progression [30], and its positivity in colorectal tumor buds indicates 
poor prognosis [31]. ABCB5 has been identified as a melanoma stem cell marker [28]. Notably, ABCG2 
has recently been correlated with asymmetric self-renewal in tissue-specific stem cells in melanoma 
[27]. Its co-expression with CXCR6, a novel asymmetric self-renewal associated gene in melanoma 
stem cells, may indicate melanoma stem cells with the most potent tumor initiating capacity [27]. 
While for cancers from mesenchymal origin, side-population-related genes (ABCG2, ABCA3, ABCB1 
and ABCC1) are considered to be the markers for cancer stem cells [28]. The high expression of 
some transporters in tumor initiating cells can result from the activation of misregulated stem cell 
factors in tumor cells. For example, stem cell factor SALL4 enhances the expression of ABCA3 by 
direct activation via binding the promoter region and ABCG2 by indirect activation, and therefore 
contributes to maintaining side population leukemic stem cells [9]. Likewise, Octamer 4 (Oct4), a 
transcription factor of pluripotent cells, is overexpressed via reduced DNA methylation and is able 
to mediate chemoresistance in hepatocellular carcinoma through a hypothetical Oct4-Akt-ABCG2 
pathway [29]. Thus, the upregulated transporters in tumors can be tumor type specific and render 
cancer cell survival advantage. Therefore, identifying the coexpression of upregulated transporters 
and stem cell factors in more tumor types will help understanding chemoresistance and overcome 
this obstacle by targeting tumor-specific transporters.
Furthermore, a recent study has discovered that in AML, leukemic-initiating cells originate from 
both lymphoid-primed multipotent progenitors (LMPPs, CD34+CD38-CD45RA+) and granulocyte-
macrophage progenitors (GMP, CD34+CD38+) [32]. Depending on their origin, the s are named 
LMPP-like or GMP-like, where the former gives rise to the latter. With respect to the gene expression 
profile, an LSC more closely resembles its normal counterpart progenitor cells [32] than the LSCs 
derived from a different progenitor. This finding is supported by one of our previous studies, which 
profiled transporter expression in CD34+CD38- and CD34+CD38+ hematopoietic cells from healthy 
donors and leukemic patients, and also demonstrated that the transporter expression pattern of 
CD34+CD38- cells from patients with leukemia was very similar to the normal CD38- HSCs, although 
the expression level in normal cells was slightly higher [1]. This may explain why the addition of ABC 
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transporter inhibitors to chemotherapy did not result in better outcome in acute myeloid leukemia. 
Incomplete eradication of leukemia stem cells is thought to contribute to disease relapse. Recent 
studies have shown that leukemia stem cells mainly reside in LMPP- and GMP-fractions. Thus it will 
be interesting to compare transporter expression profiles in these cells to normal LMPP- and GMP-
counterparts. If LMPP- and/or GMP-like LSCs express different transporters compared to normal 
counterparts, the LSCs could be targeted by inhibiting these transporters during chemotherapy. 
It would also be valuable to determine whether ABC transporter expression in LMPP- and GMP LSC 
is associated with prognostic markers like HOXA9 and CD34 [33]. 
induction of Atp-binding cassette transporter expression in leukemia cells  
in vivo following anthracyclin and cytarabine treatment
The variation of transporter expression signature in leukemic initiating cells prompted us to investigate 
ABC gene expression profiles in bulk leukemia and to determine whether their expression is regulated 
by chemotherapy. We have profiled transporter expression in CD34+ leukemic blasts from 10 patients 
receiving comparable chemotherapy (Chapter 3) and observed large variations in ABC gene expression 
among pre-treatment patient samples (Chapter 3, Figure 4). This is in line with other gene expression 
studies [34,35] indicating that pre-treatment transporter expression levels can predict therapy 
prognosis in vivo. Importantly, ABC transporters were upregulated in leukemic blasts in vivo as well 
(Chapter 3, Supplementary Table 2, Figure 4). However, in contrast to the cell line, the induction in 
vivo was highly heterogeneous in terms of type of induced transporters and induction kenetics. In 
addition, despite the observed alterations in expression after treatment, samples from the same 
individual patient grouped together in unsupervised hierarchical cluster analysis (Chapter 3, Figure 4), 
regardless of pre- or post-treatment. The validation experiments in two additional patients, whose 
leukemic blasts were treated in vitro with daunorubicin or mitoxantrone, also demonstrated individual 
tumor-based clustering (Chapter 3, Supplementary Figure 1). These data suggest that the ABC gene 
regulation induced by anti-leukemic drugs is tumor cell dependent. The differences among patients 
may be influenced by the genetic makeup of the leukemic blasts. Indeed, large differences in pre-
treatment ABC genes expression have been observed not only in various types of leukemia, but also 
within the same specific types of leukemia (like AML) [34,35]. This heterogeneity can be partially 
explained by the association between recurrent mutations in transcription factors and differential 
transporter gene expression in tumor samples [36,37]. To iron out the association between the genetic 
makeup of tumor cells and transporter regulation, future studies could be done on a larger cohort 
from one type of leukemia, which included stem cell factors in the profiling.
We also verified clear drug-dependent differences in kinetics and expression fold changes 
in KG1a cell lines (Chapter 3, Figure 3). Notably, protein levels did not always mirror mRNA levels 
proportionally (Chapter 3, Figure 4 A) for the 4 transporters we tested. The induction of transporters 
was more modest at the protein level. This can be caused by translational regulation such as 
micoRNAs. MicroRNAs involved in ABC transporter protein expression have been found for a few 
transporters, such as ABCA1 and ABCG2 [38-40]. Nonetheless, functional assays on ABCG2 showed 
that its induction resulted in enhanced efflux function (Chapter 3, Figure 4 B). These results suggest 
that the cells may protect themselves against cytostatic drugs by rapid induction of various ABC 
transporters based on the type of drug used. 
One obvious limitation of these studies is the lack of validation at the protein level, since 
efficient assays have not yet been developed. Besides affecting tumor-cell-based differences 
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in drug metabolism and pre-treatment ABC gene expression, our research indicates that the 
differential induction of ABC transporters during therapy may also affect therapy responses at the 
cellular level. The notion of tumor-cell-specific transporter induction suggested by our research 
indicates that comparisons within the same individuals during therapy could be more conclusive 
than comparisons between two cohorts for prognostic studies. This study examined changes in 
transporter expression dynamics in CD34+ leukemic cells (from de novo AML, CML blast crisis, 
relapse Pro-B-ALL and MDS progressing to AML) during therapy. A limitation of this approach is 
that the CD34+ compartment may contain several different blood cell types in addition to LSCs. So 
it will be important to determine whether the induction of transporters occurs in better defined 
LSCs (LMPP- and GMP-LSCs) and their normal counterparts. This may yield important information 
with regard to induced transporters that could be specifically inhibited to enhance the efficacy of 
chemotherapy at the leukemia stem cell level. Since new targeted therapies are increasingly used 
in the field of hemato-oncology, it will also be very important to determine whether these new 
drugs can be effluxed by ABC-transporters. It will also be important to determine whether these 
new drugs result in changes in ABC transporter expression. 
ABCB8 and ABCB10 are excluded as cancer genes in acute myeloid leukemia, 
although they are mutated in solid tumors
Numerous studies have shown that AML arises from sequential accumulation of mutations at the 
level of the hematopoietic stem/progenitor cell, which leads to the transformation in a leukemia 
initiating cell [35,41-43]. Cancers harbor a high frequency of randomly distributed somatic mutations 
[44]. An elegant systematic analysis [45] of 13,023 well-annotated human protein coding genes 
in 11 breast and 11 colorectal cancers led to the identification of 189 genes that harbored somatic 
mutations with a significant frequency and were defined as candidate cancer (CAN) genes. 
Several identified CAN genes are known to be mutated in hematological malignancies as well, 
such as ETO2, NF1, PTEN, RUNX1T1 and TP53 [46,47]. Two members of the ATP-binding cassette 
transporter superfamily are among these CAN genes for breast cancer, i.e. structurally closely 
related mitochondrial transporters ABCB8 and ABCB10, which are highly expressed in both normal 
and leukemic CD34+CD38- cells [1,2]. 
Several findings led us to hypothesize that ABCB8 and ABCB10 may harbor somatic mutations 
in AML: ABCB10 has been identified as essential for efficient cell proliferation in human mammary 
epithelial cells (HMECs) in long-term cell culture by a loss-of-function screen [48]. In addition, 
multi-drug resistance like-1 (MDL1), the yeast homologue of ABCB10, regulates cellular responses 
to oxidative stress, which is implicated in cell proliferation (neoplastic and otherwise) [49]. This 
could imply that mutations in ABCB10 – and probably ABCB8 due to the similarity in structure – 
may impair oxidative stress sensing and hence permit cancer cell growth under elevated reactive 
oxygen species (ROS) stress in AML. However, ABCB8 and ABCB10 mutation analysis did not identify 
acquired mutations. Hence they are not AML CAN genes.
ABCB8 and ABCB10 are evolutionarily highly conserved, suggesting that they have a fundamental 
function in cellular physiology. In combination with the known polymorphisms, a total of 19 (8 novel) 
variants in the ABCB8 coding region and 9 (1 novel) variants in ABCB10 are present (Figure 1). One 
non-synonymous SNP (c.1003 C4T, R304C, ABCB8) detected in our patient cohort exhibited a 
significantly different frequency (0.123) from that previously reported (0.339). The restrained variation 
in ABCB10 compared with ABCB8 might suggest that the former protein has a more conserved 
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function. Nonetheless, ABCB10 is still an interesting candidate to study due to its high expression 
in erythroid precursors [2,47] and its implication in heme synthesis and ROS sensing [24,25,49-51]. It 
will be interesting to compare the frequency of the new SNPs in AML parients and healthy controls.
ABCB10, heme and ros
Several transcription factors (such as GATA-1, SCL/TAL1, LMO2, LDB1 and KLF), together with 
epigenetic changes, orchestrate the gene expression or repression in developing erythroid cells 
[52,53]. As shown by our group and others [2,51,54], the list of most prominently induced genes 
figure 1. ABCB10 knockdown leads to reduced mitochondria content and growth disadvantage 
under oxidative stress in k562 cells. (A) (B) Transduced K562 cells were incubated with 75nM 
Mitotracker Green FM at 37 ºC for 30 min. The Mitotracker signal mean intensity represents 
the mitochondria content. Reduction of intensity X-mean in ABCB10 silencing cells is shown 
by the relative intensity to that in scrambled controls (A) and the peak shift in the histogram 
(B). (C) Transduced cells were mixed with wild type cells at 1:1 ratio and exposed to various 
concentrations of H
2
O
2 
(0, 5, 10 µM) in culture medium for 24 hours. Survival of transduced cells 
was indicated by dNGFR positivity. The dNGFR+ percentage in untreated samples (0 µM) was 
adjusted to 1. The Y axis represents the relative ratio of dNGFR+ :WT cells, which is normalized 
by untreated mixed culture samples (ratio set as 1).
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during erythroid differentiation includes several mitochondrial transporters such as ABCB6, ABCB7, 
ABCB8 and ABCB10. They have all been implicated in biosynthesis or mitochondrial transport of 
heme (ABCB6) and Fe/S clusters (ABCB7, ABCB8 and ABCB10) [15,19,22-25,54,55]. In particular, 
during murine red cell development, Abcb10 gene expression is strongly induced by GATA-1, 
and its overexpression enhances hemoglobin formation [50,51], which strongly supports the 
role of ABCB10 in heme syntheses and hence in erythroid development. In agreement with this 
finding, we recently observed that ABCB10 is the most highly expressed transporter in CD71+ 
erythroid precursors [2]. Furthermore, we found that the silencing of ABCB10 in K562 cells resulted 
in reduced hemoglobinization (Chapter 5) [56]. These findings prompted us to study the role of 
ABCB10 in erythroid development, using primary CD34+ hematopoietic cells as a differentiation 
model. To this end, we silenced ABCB10 expression in erythroleukemia K562 cells and human 
primary CD34+ hematopoietic cells and subjected them to erythroid differentiation. Abnormality in 
hemoglobinizition was observed for K562 cells and reduction in red colony formation was observed 
in primary CD34+ cells (Chapter 5).
Under Ara-C treatment, the gene knockdown cells could still undergo differentiation, but with 
a considerably compromised capacity to synthesize hemoglobin, indicated by weaker induction of 
erythroid markers (CD71 and GPA) and reduced hemoglobin synthesis (Chapter 5, Figure 1). We then 
looked at the consequence of ABCB10 abrogation in more primitive CD34+ multipotent progenitor 
cells, which possess both erythroid and myeloid potential, by examining their clonogenic capacity. 
Strikingly, red colony numbers declined dramatically (about 80%) in ABCB10 knockdown cultures 
compared to controls (Chapter 5, Figure 2 A). ABCB10 silencing also led to smaller red colonies and 
lack of efficient burst-forming-unit erythroid formation (Chapter 5, Supplementary Figure 1). In line 
with this finding, forced expression of mouse Abcb10 has been shown to indirectly enhance heme 
synthesis in differentiated MEL cells through interactions with the iron importer mitoferrin-1 (Mfrn1) 
and the heme synthesizing enzyme ferrochelatase (Fech) [24,25]. Morphological analysis showed 
a dramatic decrease of all differentiation stages (ortho-erythroblasts, pro-erythroblasts as well as 
enucleated erythroid cells) along the erythroid lineage following ABCB10 knockdown (Chapter 5, 
Figures 2 C and 2 D). This led to the hypothesis that ABCB10 is required at the early stages of red blood 
cell development. This was supported by a recent study demonstrating very high ABCB10 expression in 
at early erythroid stages (erythroid colony forming cells, pro- and intermediate erythroblast) followed 
by a sharp decrease in expression at the late erythroblast stage [54]. These findings suggest that ABCB10 
may have functions early during differentiation that are unrelated to Mfrn1 stabilization [24,25,54]. 
Interestingly, a significant increase in the number of white colonies following ABCB10 knockdown 
was consistently observed in the CFU assays (Chapter 5, Figure 2 A). This can be explained by 
regulation of reactive oxygen species. Increases in reactive oxygen species have been linked to 
induction of myeloid differentiation [57-59]. A recent study has revealed that inactivation of 1 
allele of ABC-me increases the mitochondrial oxidative stress in hearts after ischemia/reperfusion 
[60]. These findings suggest that a compromised ABCB10 protein level could lead to increased 
myeloid differentiation via increased cellular oxidative stress. Indeed, our most recent studies 
demonstrated a growth disadvantage of ABCB10 knockdown in K562 cells under oxidative stress and 
reduced mitochondrial content after ABCB10 abrogation (Figure 1, data not published). However, 
alternative mechanisms for the decrease in red colonies and the increase in white colonies cannot be 
excluded, such as the inhibition of ABCB10 on the clonogenic capacity of granulocyte-macrophage 
progenitors, and the redirecting of erythroid differentiation into the granulocytic/monocytic lineage 
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in the absence of ABCB10. In addition, previously published work showed that forced expression of 
mouse Abcb10 does not trigger spontaneous differentiation of MEL cells [51], which implies that 
ABCB10 may not be an active driver for erythroid differentiation. 
Nevertheless, due to the above findings ABCB10 has been added to a growing list of mitochondrial 
transporters (such as ABCB6 [61] and ABCB7 [20]) that are important for proper red blood cell 
development. Likewise, Shirihai et al. have revealed that ABC-me is essential for erythropoiesis 
in vivo and that the defective erythropoiesis caused by ABCB10 deletion could be partially due to 
mitochondrial oxidative damage [62]. To understand exactly how ABCB10 contributes to blood 
cell development, it will be interesting to identify its substrates, which could be oxidized peptides 
that would increase mitochondrial oxidative stress [60,63,64]. In addition, it has been shown that 
enhanced ABCB10 expression increases heme synthesis. Since the four mitochondrial transporters 
ABCB6, ABCB7, ABCB8 and ABCB10, are all involved in Fe/S cluster transport and heme synthesis, 
it will also be important to figure out whether these genes are co-regulated. Potentially, ABCB10 
expression stimulation by novel small molecules may enhance hemoglobin synthesis in pathological 
conditions such as blood loss or anemia. 
suggestions for future research
We suggest that future research address the following aims (i) efficiently bypassing multidrug 
resistance in cancer treatment, (ii) determining the picture and meaning of transporter signatures 
in various cancer stem cells and (iii) defining the exact mechanism by which ABCB10 balances red 
and white blood cell development. We can offer following clues to support this future research.
Bypassing multidrug resistance 
The success of ABC transporter inhibitors to enhance the effect of cytostatic effects has been limited 
by the severe toxic effects at the doses required for in vivo target inhibition or by the interference 
with the pharmacokinetics of the co-administered drugs. P-glycoproteins function as “molecular 
vacuums” that pool substrates directly from the cell membrane [65]. Unbound conventional drugs 
are often internalized by diffusion across cell membranes, making them spatially vulnerable to 
P-glycoprotein capture and efflux. One promising approach to circumvent MDR could be the use of 
multifunctional nanoparticles that encapsulate therapeutics into nanocarriers made of liposomes, 
micelles, nanoemulsions, polymers or dendrimers [26,66,67]. In contrast, these nanoparticles 
are internalized via non-specific endocytosis (or facilitated uptake of targeted nanocarriers), 
forming endosomes that internalize and release drugs near the peri-nuclear region and away from 
membrane-bound ABC transporters such as P-glycoproteins. Consequently, the nanocarriers can 
bypass the capture and efflux of ABC transporters. They can also be equipped with targeting ligands 
that provide multivalent binding to the surface of tumor cells and can be engineered to encapsulate 
siRNAs that silence certain transporters. Due to these features, multifunctional nanoparticles are 
a promising option to overcome MDR.
identifying the transporter signature in gmp- and lpmm-like leukemia 
initiating cells
The characterization of leukemia initiating cells that exhibit both CD38-CD45RA+ lymphoid-primed 
multipotent progenitor (LMPP) or CD38+ GMP phenotype and stem cell self-renewal ability raises 
the possibility of the progenitor origin of leukemic stem cells [32]. This avoids the major effort 
required to compare the transporter signature in leukemia initiating cells with normal HSCs, which 
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do not represent the appropriate site of malignant transformation. GMP-leukemia initiating cells 
are reprogrammed, which is revealed by their global mRNA expression. It will then be important 
to acquire a picture of transporter expression in the LMPP- and GMP-like leukemia initiating cells 
and compare it with the corresponding normal progenitors. This will shed light on the deregulation 
of ABC transporters at the site of malignant transformation. Several self-renewal markers, such as 
SALL4, Oct4, CXCR6 [9,27,29], can be included in the analysis to reveal the correlation between 
these factors and transporter modulation. The notion of tumor cell dependent overexpression 
of transporters implies that the pattern of transporter misregualtion could be associated with 
the origin of tumore cells. Thus therapy could be directed towards tumor (sub)type-specific ABC 
transporters rather than targeting common drug transporters.
ABCB10 in mitochondrial function and erythroid development
Because reactive oxygen species can induce myeloid differentiation in hematopoietic cells [57-59], 
we hypothesized that compromised ABCB10 protein may lead to increased myeloid differentiation 
via elevated cellular oxidative stress in the presence of differentiation agents. One could verify 
this by using ROS scavengers after ABCB10 knockdown and examining whether the phenotype is 
reversible. The research by Hyde et al suggests that ABCB10 activity is crucial to avoid mitochondrial 
oxidative damages by superoxide generated during heme synthesis and that the defects in erythroid 
development caused by ABCB10 abrogation are partially restored by an antioxidant [62]. Therefore, a 
proposed strategy to elucidate its role in regulating oxidative stress sensing is to first generate various 
compromised levels of ABCB10 in cell models with and without ROS scavengers, followed by functional 
study on mitochondria rather than heme synthesis per se. The observations could be directed 
towards mitochondrial fission and fusion, mitochondrial potential, intracellular or mitochondrial 
reactive oxygen species levels and induced oxidative damage. It will be also interesting to study which 
type of ROS is induced under ABCB10 defeciency. Another important objective will be to identify 
the substrate of ABCB10, which is still unknown. It is assumed to be oxidized peptides, which could 
explain its capacity to regulate oxidative stress sensing. It is worthy to investigate the role of ABCB10 
in erythroid leukemia by mutation screen and searching genes responsible for ABCB10 activation.
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Additional files from chapter 2
supplementary table 1. Genes defining HSCs from other stem cells. Mann-Whitney U-test of genes defining 
HSCs from other SC sources. The significance is indicated by a bootstrap value below 0.05. The genes with 
shaded areas show the largest fold differences.
gene Bootstrap median (hsC) median (non_hsC)
median (hsC) / 
median(non-hsC)
ABCA2 0,00E+00 5,74E-02 6,37E-03 9,01E+00
ABCA3 0,00E+00 7,96E-03 1,70E-04 4,68E+01
ABCA5 0,00E+00 1,89E-02 1,14E-03 1,66E+01
ABCA7 0,00E+00 2,37E-02 4,14E-04 5,71E+01
ABCB1 0,00E+00 2,89E-02 2,05E-06 1,41E+04
ABCB10 0,0005 2,28E-02 6,11E-03 3,73E+00
ABCB2 0,00E+00 4,52E-02 5,78E-03 7,81E+00
ABCB3 0,0035 2,72E-02 3,20E-03 8,50E+00
ABCB7 0,00E+00 3,78E-02 6,41E-03 5,90E+00
ABCB9 0,0285 3,37E-03 1,05E-03 3,20E+00
ABCC1 0,00E+00 5,60E-02 7,74E-03 7,24E+00
ABCC10 0,00E+00 7,90E-03 2,36E-03 3,35E+00
ABCC5 0,00E+00 1,14E-02 2,49E-03 4,58E+00
ABCD1 0,00E+00 9,95E-03 2,78E-03 3,58E+00
ABCD4 0,00E+00 2,94E-02 2,39E-03 1,23E+01
ABCG1 0,00E+00 1,91E-02 6,12E-06 3,12E+03
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supplementary table 2. Combination of ABC transporter genes unique for each subgroup of cells. Kruskal–Wallis 
tests identified sets of genes distinct for each subgroup of non-HSCs and mature blood cells. The significance 
is represented by a bootstrap value below 0.05. Median (yes) is the median value of all samples within this 
subgroup. Median (no) represents the median value of the other samples. The genes with shaded areas exhibit 
the largest fold differences.
Cell type gene Bootstrap median (no) median (yes)
median(yes)/ 
median(no)
Non-HSC
MSC
ABCG5 0,01 5,40E-07 1,33E-07 2,46E-01
ABCC13 0,02 4,63E-07 1,33E-07 2,88E-01
ABCG8 0,02 5,39E-07 1,33E-07 2,47E-01
ABCC11 0,02 3,83E-07 1,33E-07 3,48E-01
ABCC12 0,02 3,83E-07 1,33E-07 3,48E-01
ABCA6 0,02 6,16E-05 5,95E-04 9,65E+00
ABCC7 0,04 9,84E-07 1,40E-07 1,43E-01
USSC ABCD4 0,01 3,44E-03 1,30E-03 3,78E-01
MAPC
ABCA13 0 3,97E-06 2,47E-04 6,22E+01
ABCC2 0 2,99E-05 3,31E-04 1,11E+01
ABCC9 0 5,18E-04 1,10E-02 2,12E+01
ABCG1 0 1,62E-05 2,33E-07 1,44E-02
ES
ABCA3 0 1,45E-04 4,94E-03 3,42E+01
ABCA7 0 3,16E-04 2,42E-03 7,64E+00
ABCA8 0 2,51E-03 6,56E-07 2,61E-04
ABCB7 0 4,85E-03 2,45E-02 5,04E+00
ABCC5 0 2,34E-03 6,27E-03 2,68E+00
ABCC7 0 4,50E-07 1,65E-04 3,67E+02
ABCC8 0 2,69E-07 1,31E-04 4,88E+02
ABCC9 0 1,11E-03 9,13E-06 8,23E-03
ABCD4 0 2,36E-03 1,24E-02 5,25E+00
ABCG2 0 7,92E-05 1,28E-03 1,61E+01
Mature 
blood cells
NK
ABCA2 0 5,27E-03 2,42E-01 4,59E+01
ABCA3 0 5,71E-05 6,74E-03 1,18E+02
ABCB1 0 7,69E-05 3,19E-02 4,15E+02
ABCD2 0 6,00E-05 1,43E-02 2,38E+02
CD71+
ABCA4 0 2,95E-05 1,06E-03 3,58E+01
ABCA6 0 3,45E-04 1,87E-03 5,43E+00
ABCB10 0 1,30E-02 2,03E+00 1,57E+02
ABCB2 0 2,43E-01 1,74E-02 7,17E-02
ABCB3 0 1,41E-01 1,74E-02 1,24E-01
ABCB5 0 6,24E-06 4,30E-03 6,89E+02
ABCB6 0 1,98E-03 4,81E-01 2,43E+02
ABCB7 0 2,28E-02 2,00E-01 8,76E+00
ABCB8 0 1,66E-02 6,24E-02 3,76E+00
ABCB9 0 2,34E-04 8,26E-03 3,53E+01
ABCC13 0 2,71E-05 6,67E-02 2,46E+03
ABCC4 0 5,71E-04 8,15E-02 1,43E+02
ABCC5 0 1,13E-02 1,38E-01 1,22E+01
ABCD1 0 1,91E-02 4,12E-03 2,15E-01
ABCD3 0 7,59E-03 1,08E-01 1,43E+01
ABCG2 0 5,90E-05 6,06E-02 1,03E+03
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Additional files from chapter 3
supplementary figure 1. tumor cell-specific clustering in unsupervised hierarchical clustering 
analysis is observed for in vitro study. Leukemic blasts from two AML patients were treated 
in vitro by mitoxantrone or daunorubicin. The samples grouped predominantly according to 
patients but not drug exposure. In the same patient, the treated samples clustered separately 
from untreated samples.
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supplementary table 2. Top 10 induced transporters in KG1a cell line and in vitro patient samples.
(A) Top 10 induction by mitoxantrone or daunorubicin in KG1a cells.
fold mito (48h) fold dauno (72h) fold Ara-C (72h)
ABCC6 431,847 ABCC6 1217,050 ABCC6 282,708
ABCG8 174,034 ABCA4 742,149 ABCG2 25,149
ABCA4 170,428 ABCG1 293,205 ABCB11 12,123
ABCG4 122,942 ABCC13 226,138 ABCA6 11,020
ABCG5 91,309 ABCD2 199,550 ABCG4 10,993
ABCG1 75,363 ABCA12 196,306 ABCC3 9,625
ABCA12 47,126 ABCG4 162,449 ABCG5 8,497
ABCC12 42,523 ABCC9 144,707 ABCA5 7,785
ABCC9 40,543 ABCC7 125,075 ABCA10 4,937
ABCB11 38,161 ABCA10 123,188 ABCC9 4,927
(B) Top 10 induced transporters for in vitro patient study by mitoxantrone or daunorubicin.
mitoxantrone
patient 11 patient 12
gene fold induction gene fold induction
ABCA5 421 ABCG4 626
ABCB6 55 ABCB1 21
ABCG2 26 ABCG2 21
ABCC3 20 ABCB6 19
ABCB4 7,9 ABCB7 16
ABCA7 5,2 ABCA7 16
ABCC6 4,3 ABCC5 9,5
ABCB8 4,1 ABCC2 9,3
ABCA1 3,6 ABCA5 8,6
ABCG1 8,1
daunorubicin
patient 11 patient 12
gene fold induction gene fold induction
ABCB6 126 ABCA8 106
ABCA3 9,1 ABCA10 92
ABCC3 8,5 ABCA6 55
ABCA1 8,4 ABCC9 52
ABCC6 8,1 ABCB11 52
ABCB4 5,6 ABCG2 8,4
ABCC5 5,4 ABCA9 7,7
ABCB8 5,1 ABCB6 5,4
ABCB2 4,8 ABCC2 3,3
ABCA7 4,7 ABCC5 3,1
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SUMMARY
 summAry
ABC transporters export or import a large variety of endogenous and exogenous agents across 
membranes, driven by the hydrolysis of ATP at nucleotide binding domain (NBD) sites upon binding 
of a substance. Multiple roles of ABC transporters have been described in hematopoiesis. Cholesterol 
efflux by ABCA1 and ABCG1 restrains hematopoietic stem cell proliferation. Intracellular transport 
of Fe/S cluster coordinated by ABCB6, ABCB7 and ABCB10 is essential for heme synthesis. The 
transporters associated with antigen processing, TAP1 (ABCB2) and TAP2 (ABCB3), mediate cellular 
immune defense against infected or malignantly transformed cells. Importantly, the induction of 
sets of transporters during cancer therapy confers chemoresistance. 
This thesis describes our research into the role of transporters in both normal (Chapter 2 
and 5) and malignant (Chapter 3 and 4) hematopoiesis, especially in erythroid development. 
Hematopoeitic stem cells (HSCs) express a large number of ABC transporters at a high level. This 
may contribute to lifelong protection against xenobiotics. Whether stem cells other than HSCs 
express a similar repertoire of ABC transporters is unknown. Our research into ABC transporter 
expression in non-HSCs, including unrestricted somatic stem cells (USSCs), mesenchymal stem cells 
(MSCs), embryonic stem cells (ESCs) and multipotent adult progenitor cells (MAPCs), is described in 
Chapter 2. We found that unrelated non-HSCs exhibited a remarkably similar transporter expression 
profile that differed significantly from HSCs, but we also identified sets of ABC transporters that are 
characteristic for non-HSC subtypes. Based on these findings, we concluded that non-HSCs rely 
on different sets of transporters compared to HSCs, which are closely related to the physiology of 
a specific stem cell type. To verify whether the high expression of transporters is unique to stem 
cells, we measured ABC gene expression profiles in various mature blood cell types including 
monocytes, granulocytes, CD71+ erythroid progenitors, T cells and NK cells. However, most 
transporters exhibited a higher level in at least one of the mature blood cell types compared to 
HSCs. Most ABC genes that are specifically highly expressed in each mature blood cell fraction are 
associated with functions that are characteristic for the cell type. 
Prolonged exposure to cytostatic drugs may trigger drug resistance through induction of 
ABC transporters. It was unknown whether this phenomenon also occurs rapidly in vivo during 
chemotherapy. Chapter 3 contains a description of our investigation of ABC gene expression following 
chemotherapy in vivo, where we profiled transporter expression in CD34+ leukemic blasts from 10 
leukemia patients receiving comparable chemotherapy. Large variations were observed in terms 
of numbers of expressed transporters, expression level and types of transporters among patient 
samples before treatment. Following treatment with cytostatic drugs, great heterogeneity of induced 
transporters and upregulation of gene expression was also observed in cells isolated from patients during 
treatment. Notably, despite the alterations in expression after treatment, pre- and post-treatment 
samples did not cluster separately in unsupervised hierarchical clustering analysis. In fact, samples 
taken from each patient clustered together. The ABC gene upregulation following chemotherapy 
was verified by in vitro experiments at both the mRNA and protein level. These findings suggest that 
anti-leukemic drug induced ABC gene regulation is tumor cell dependent. The differences between 
patients could be influenced by the genetic makeup of leukemic blasts, which is discussed in Chapter 6.
Numerous studies have shown that AML arises from sequential accumulation of mutations 
at the level of HSCs/HPCs. Two mitochondrial transporter genes, ABCB8 and ABCB10, have been 
identified as cancer candidate genes in breast cancers and colorectal cancers. They are highly 
expressed in both normal and leukemic stem/progenitor cells. Because there is substantial overlap 
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of cancer genes in solid tumors and hematological malignancies, we also looked for mutations in 
ABCB8 and ABCB10 in leukemia. Mutation screening of these two genes was performed in a panel 
of 94 AML patients by heteroduplex analysis, as described in Chapter 4. However, no acquired 
mutations were identified for ABCB8 and ABCB10, so they were excluded as cancer candidate 
genes for AML. Nonetheless, we did find several novel SNPs/germline variants. Including known 
polymorphisms, a total of 19 variants (8 novel) in the ABCB8 coding region and 9 variants (1 novel) 
in ABCB10 were found. The restrained variation in ABCB10 (compared with ABCB8) might suggest 
that it has a more conserved function.
Notably, ABCB10 is one of the most prominently induced genes during erythroid differentiation 
and is known to be involved in heme synthesis and ROS sensing. Therefore, as described in Chapter 5, 
we proceeded to investigate the function of ABCB10 in red blood cell development by means of 
gene expression silencing. After knockdown of ABCB10, erythroleukemia K562 cells could still 
undergo differentiation, but with a considerably compromised capacity to synthesize hemoglobin. 
In human primary CD34+ hematopoietic cells, ABCB10 silencing led to a reduction in red colony 
number and lack of efficient burst-forming-unit erythroid formation in CFU assays. Morphological 
analysis following ABCB10 knockdown showed a dramatic decrease in all differentiation stages 
along the erythroid lineage. Interestingly, the gene silenced CD34+ cells exhibited a significant 
increase in the number of white colonies, likely via increased cellular oxidative stress caused by 
the absence of ABCB10. This is discussed in Chapter 6. As a result of this finding, ABCB10 can be 
added to a growing list of mitochondrial transporters (ABCB6 and ABCB7) that are important for 
proper red blood cell development. 
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sAmenVAtting in het nederlAnds
ABC-transporters pompen endogene en exogene stoffen door membranen. Het gaat hierbij om 
actief, ATP-afhankelijk transport, waarbij stoffen geïmporteerd maar ook geëxporteerd kunnen 
worden. Het transport vindt plaats door het celmembraan maar ook intracellulair kunnen door 
ABC-transporters stoffen actief door membranen getransporteerd worden. ABC-transporters spelen 
een belangrijke rol bij de bloedcelaanmaak. Zo remmen de transporters ABCA1 en ABCG1 de groei 
van bloedstamcellen door cholesterolexport. Een ander voorbeeld betreft intracellulair transport 
van ijzer/zwavel-clusters. Dit transport is nodig voor de synthese van heem zodat bijvoorbeeld 
hemoglobine gevormd kan worden. Het transport van ijzer/zwavel-clusters wordt gereguleerd 
door de mitochondriële transporters ABCB6, ABCB7 en ABCB10. De transporters ABCB2 en ABCB3 
dragen bij aan antigeenpresentatie, en daarmee aan immunologische afweer. De afgelopen 10 jaar 
is duidelijk geworden dat de activatie van ABC-transporters chemoresistentie kan veroorzaken. Dit 
proefschrift beschrijft ons onderzoek naar de rol van ABC-transporters tijdens normale (Hoofdstuk 
2 en 5), en maligne (Hoofdstuk 3 en 4) bloedcelaanmaak. 
Bloedstamcellen, ook wel hematopoïetische stamcellen (HSC) genoemd, brengen een groot 
aantal ABC-transporters hoog tot expressie. Dit draagt bij aan de levenslange bescherming van HSC 
tegen stoffen die bedreigend voor ze zijn. Of andere stamcellen dan HSC een vergelijkbare expressie 
van ABC-transporters vertonen is onbekend. Ons onderzoek naar ABC-transportergenexpressie in 
niet-HSC, zoals somatische -, mesenchymale -, embryonale - en multipotente adulte progenitor 
stamcellen, is beschreven in Hoofdstuk 2. We vonden dat ongerelateerde niet-HSC een opmerkelijk 
vergelijkbaar transporter-genexpressieprofiel lieten zien, dat significant verschilt van HSC. Er werden 
echter ook enkele ABC transporters geïdentificeerd die karakteristiek zijn voor de verschillende 
onderzochte niet-HSC. Deze bevindingen suggereren dat niet-HSCs van andere transporters 
afhankelijk zijn voor hun functie dan HSC. Om te bepalen of de hoge expressie van transporters 
uniek is voor HSC, hebben we in Hoofdstuk 2 ook onderzocht hoe de expressie zich verhoudt ten 
opzichte van rijpe bloedcellen, zoals monocyten, granulocyten, CD71+ erytroïde voorlopercellen, 
T-cellen en NK-cellen. Een opvallende bevinding was dat voor bijna elke transporter een of meerdere 
rijpe bloedceltypes gevonden werd waarin deze hoger tot expressie kwam dan in HSC. Veel van 
deze ABC transporters vervullen een functie die specifiek is voor de rijpe bloedceltypes waarin ze 
hoog tot expressie komen. 
Een langdurige blootstelling aan cytostatica kan resulteren in chemoresistentie door activatie 
van ABC-transporters. Het is onbekend of dit fenomeen ook direct in vivo optreedt tijdens 
blootstelling van cellen aan chemotherapie. In Hoofdstuk 3 hebben we dit onderzocht door 
de genexpressie van ABC-transporters in CD34+ leukemiecellen te meten in een groep van 10 
patiënten die vergelijkbare chemotherapie kregen. In de leukemiecellen van alle 10 onderzochte 
patiënten werd inderdaad een verhoging van ABC-transportergenexpressie gevonden. Echter, een 
vergelijking tussen de ABC-genexpressieprofielen in leukemiecellen van de 10 patiënten voor en 
na chemotherapie lieten geen significante verschillen zien op basis waarvan met chemotherapie 
behandelde cellen geïdentificeerd konden worden. Dit wordt waarschijnlijk veroorzaakt door sterke 
verschillen in ABC-transportergenexpressie in leukemiecellen van de verschillende patiënten voor 
aanvang van de behandeling. Ook werd er tussen de patiënten grote variatie gevonden in het aantal 
transporters dat verhoogd tot expressie kwam. Daarnaast verschilde ook de mate van verhoogde 
genexpressie sterk. Mogelijk worden deze verschillen veroorzaakt door verschillen in de genetische 
opmaak van de leukemiecellen van de patiënten. Concluderend kan gesteld worden dat er geen 
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unieke set van transporters bestaat die uniform verhoogd tot expressie komt na blootstelling van 
leukemiecellen aan chemotherapie in de door ons onderzochte patiëntengroep. 
Onafhankelijke studies hebben aangetoond dat acute myeloïde leukemie (AML) ontstaat door 
een opeenhoping van mutaties in hematopoïetische stam- of voorlopercellen. De mitochondriële 
transportergenen ABCB8 en ABCB10 zijn potentiële kankergenen in borstkanker en darmkanker. 
Deze genen komen hoog tot expressie in zowel normale als leukemiestam- en voorlopercellen. 
Omdat er een significante overlap is tussen kankergenen die betrokken zijn bij het ontstaan van 
solide tumoren en hematologische maligniteiten, hebben we onderzocht of ABCB8 en ABCB10 
gemuteerd zijn bij AML. Mutatiescreening van deze twee genen is uitgevoerd met heteroduplex 
analyse op materiaal van 94 AML-patiënten, zoals beschreven in Hoofdstuk 4. Met deze analyse 
werden geen verworven mutaties in ABCB8 en ABCB10 gevonden. Deze genen spelen zeer 
waarschijnlijk dan ook geen rol bij het ontstaan van AML. Wel werd een aantal variaties in het 
DNA van ABCB8 en ABCB10 gevonden. Het gaat hier bij om variaties die ook bij gezonde individuen 
gevonden worden. Inclusief de reeds bekende DNA-variaties werden in totaal 19 varianten gevonden 
(waarvan 8 nieuwe) in ABCB8 en 9 varianten (waarvan 1 nieuwe) in ABCB10. Het relatief lage aantal 
varianten in ABCB10 (vergeleken met ABCB8) suggereert dat ABCB10 een functie heeft die sterker 
geconserveerd is tijdens de evolutie dan dat voor ABCB8 het geval is.
Genexpressiestudies hebben aangetoond dat ABCB10 één van de meest geactiveerde genen is 
tijdens de rode bloedceldifferentiatie. Het ABCB10 eiwit is betrokken bij de synthese van heem en 
het detecteren van zuurstofradicalen. In Hoofdstuk 5 hebben we onderzocht wat de functie van 
ABCB10 is tijdens de rode bloedcelontwikkeling, door de expressie van ABCB10 te verminderen. Dit 
is onder andere gedaan in de humane cellijn K562. K562-cellen kunnen geforceerd worden uit te 
rijpen naar voorloper-rode bloedcellen. Na het verminderen van de genexpressie van ABCB10 bleken 
K562-cellen nog wel uit te kunnen rijpen. Echter, de hemoglobineproductie was significant lager. 
Het verminderen van ABCB10-genexpressie in onrijpe humane CD34+ bloedcellen resulteerde in 
een sterke reductie in de vorming van rode bloedcelkolonies. Morfologische analyses lieten zien dat 
er op alle erytroïde maturatiestadia een sterke celreductie was. Wat verder opviel was dat reductie 
van ABCB10-genexpressie in een significante toename in de vorming van witte bloedcelkolonies 
resulteerde. Zoals besproken in Hoofdstuk 6 wordt dit mogelijk veroorzaakt door een toename 
in oxidatieve stress. Concluderend kan gesteld worden dat ABCB10, net als ABCB6 en ABCB7, een 
belangrijke rol speelt bij de vorming van rode bloedcellen.
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